IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Autologous Cell Therapies for Cerebral Palsy -Chronic  
(ACT for CP)  
 
[STUDY_ID_REMOVED]  
 
Version Date: 10/23/2017  
  
IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Autologous Cell Therapies for 
Cerebral Palsy -Chronic  
(ACT for CP) 
Phase II  
Principal Investigators: 
Charles S. Cox, Jr., M.D.  
The George and Cynthia Mitchell Distinguished Chair in Neurosciences 
Director, Children’s Program in Regenerative Medicine  
Professor, Department of Pediatric Surgery 
UTHealth McGovern Medical School at Houston  
 
||||||||||||||||||||||||||||||||||||||||||||||| | 
 
 
Sean I. Savitz, M.D.  
Professor, Department of Neurology 
UTHealth McGovern Medical School at Houston  
||||||||||||||||||||||||||||||||||||||||||||| | 
 
 
 
 
 
CPHS: HSC -MS-12-0876 
||||||||||||||||||| | 
Study Registry ID: [REMOVED]  
 
||||||||||||||||||||||||||||||||||||||| | ||||||||||||||||||||||||||||||||| | ||||||||||||||||||||||||||||||||||||||| | 
 
 
Sponsor: TIRR Foundation, CBR, Inc., and Let’s Cure CP Foundation  
IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Title:  Autologous Cell Therapies for Cerebral Palsy -Chronic (ACT for  CP) 
IND Sponsor  Charles S. Cox, Jr.,  MD 
and Principal  The George  and Cynthia  Mitchell  Distinguished  Chair  in Neurosciences  
Investigator:  Director, Children’s Program in  Regenerative  Medicine 
Professor, Departments of Sur gery and Pediatric Surgery 
UTHealth, McGovern Medical School at  Houston  
Co-Principle  Sean I. Savitz, MD, Professor, Department of  Neurology  
Investigator:  UTHealth, McGovern Medical School at  Houston  
Co-Investigators:  Fabio Triolo, PhD, Associate  Professor  
University of Texas Health Science Center at Houston  
Maria Matuszczak, MD, Professor, Department of Anesthesiology 
UTHealth, McGovern Medical School at Houston  
Jennifer Juranek, PhD, Associate Professor in Pediatric Research 
UTHealth, McGovern Medical Scho ol at Houston  
Allison Dempsey, PhD, Assistant Professor, Department of Pediatrics 
UTHealth, McGovern Medical School at Houston  
Biostatistician:  Claudia Pedroza, PhD.  Assistant  Professor  
UTHealth, McGovern Medical School at Houston  
Research  Jade Kumar, MD.   Research Fellow, Department  of 
Residents:  Pediatric Surgery UTHealth, McGovern Medical School at  Houston  
Louis Carrillo, MD.  Research Fellow, Department of  
Pediatric Surgery UTHealth, McGovern Medical School at Houston  
Study  Steven C. Kosmach, MSN, RN,  CCRC  
Coordinators:  Clinical Trial Program Manager, Department of  Pediatric  Surgery  
UTHealth, McGovern Medical School at  Houston  
Joiya Arrington, MSN, RN  
Senior Research Nurse, Department of Pediatric Surgery 
UTHealth, McGovern Medical School at Houston  
Clinical  Site:  Children’s Memorial Hermann  Hospital  
6411 Fannin, Houston, TX 77030  
UT Health Pediatric Surgery Clinic  
6410 Fannin, St 1400, Houston, TX 77030  
Laboratories:  Memorial Hermann Hospital  Laboratory  
6411 Fannin, Houston, TX 77030  
The Evelyn H. Griff in Stem Cell Therapeutics Research Laboratory 
UTHealth Behavioral & Biomedical Science Building  
1941 East Rd., BBSB 6102A, Houston, TX 77054  
IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017  ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 3 of 49   TABLE OF CONTENTS  
1. STUDY  OBJECTIVES…  ................................ ................................ ..............................  6 
1.1 Primary  Objective…  ................................ ................................ ..........................  6 
1.2 Secondary  Objectives…  ................................ ................................ ...................  6 
2. BACKGROUND…  ................................ ................................ ................................ ....... 6 
2.1 Rationale for Initiating Protocol  in Children…  ................................ ....................  6 
2.2 Pre-Clinical  Data  ................................ ................................ ...............................  7 
3. STUDY  DESIGN…  ................................ ................................ ................................ ....... 8 
4. SELECTION AND ENROLLMENT  OF SUBJECTS…  ................................ .................  9 
4.1 Inclusion  Criteria…  ................................ ................................ ...........................  9 
4.2 Exclusion  Criteria…  ................................ ................................ ..........................  9 
5. STUDY  INTERVENTIONS…  ................................ ................................ ........................  10 
5.1 Bone  Marrow  Arm…  ................................ ................................ .........................  10 
5.1.1  Subject  Recruitment…  ................................ ................................ ...... 10 
5.1.2  Randomization…  ................................ ................................ ..............  10 
5.1.3  Baseline Visit and Bone Marrow  (Placebo)  Harvest/Infusion  ............  11 
5.1.4  Sham  Harvest  Procedure…  ................................ ..............................  11 
5.1.5  Schedule of  Vital Signs…  ................................ ................................ .. 12 
5.1.6  BMMNC  Dosing…  ................................ ................................ .............  12 
5.1.7  Post-Infusion  Period…  ................................ ................................ ...... 12 
5.1.8  Cross -over and  Follow -up Visits…  ................................ ....................  13 
5.1.9  Blinding of  Placebo  Infusion…  ................................ ..........................  13 
5.2 Cord  Blood  Arm…  ................................ ................................ .............................  14 
5.2.1  hUCB Collection, Processing,  and Storage…  ................................ ... 14 
5.2.2  CBR hUCB  Sample  Quality…  ................................ ...........................  14 
5.2.3  Subject  Recruitment  ................................ ................................ ..........  14 
5.2.4  Maternal Infectious  Disease  Testing  ................................ .................  15 
5.2.5  Randomization…  ................................ ................................ ..............  15 
5.2.6  Shipping of  Cord  Blood…  ................................ ................................ .. 16 
5.2.7  Baseline Visit and Cord Blood  (Placebo)  Infusion  .............................  16 
5.2.8  Schedule of  Vital Signs.  ................................ ................................ .... 16 
5.2.9  Post-Infusion  Period…  ................................ ................................ ...... 17 
5.2.10  Cross -over and  Follow -up Visits…  ................................ ....................  17 
5.3 Handling of Cord  Blood/Bone  Morrow/Placebo  Products…  ..............................  18 
5.4 Pre-Infusion Medications  (All Groups)…  ................................ ...........................  18 
5.5 Prohibited  Interventions…  ................................ ................................ ................  18 
6. CLINICAL AND  LABORATORY  EVALUATIONS…  ................................ ....................  18 
6.1 Schedule  of Events…  ................................ ................................ .......................  18 
6.2 Infusion  Toxicity  Complications…  ................................ ................................ ..... 18 
6.2.1  Hemodynamic  Instability…  ................................ ................................  18 
6.2.2  Pulmonary  Complications…  ................................ ..............................  19 
6.2.3  Hepatic  Injury…  ................................ ................................ ................  19 
IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017  ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 4 of 49   6.2.4  Renal  Complications…  ................................ ................................ ..... 19 
6.2.5  Neurologic  Complications…  ................................ ..............................  20 
6.3 Psychological  Assessment  Battery………………………………………….  20 
6.3.1  Motor  Functioning…  ................................ ................................ ..........  20 
6.3.2  Quality of  Life…  ................................ ................................ ................  20 
6.3.3  Adaptive Behavior Functioning…  ................................ ......................  20 
6.3.4  Visual -Spatial  Processing  ................................ ................................ . 21 
6.3.5  Learning/Memory  ................................ ................................ ..............  21 
6.3.6  Expressive and Receptive  Vocabulary  ................................ ..............  21 
6.4 MRI Evaluation…  ................................ ................................ ..............................  21 
6.4.1  CP Neuroimaging…  ................................ ................................ ...........  21 
6.4.2  MRI Acquisition  and Analysis…  ................................ .........................  22 
6.4.3  Anatomical  MRI Analysis…  ................................ ................................  23 
6.4.4  Freesurfer Analyses of Cortical and  Subcortical  Volumes…  ..............  24 
6.4.5  DTI Processing  and Analysis… ................................ ..........................  25 
6.4.6  DTI Co -Registration with Same  Subject’s  aMRI…  .............................  25 
6.4.7  Region of Interest and Fiber Tracking Analysis for  DTI Data…  ..........  25 
6.4.8  MRI Quality Control  Procedures…  ................................ .....................  27 
6.4.9  Secondary Imaging Outcome Measures and  Correlation  
with Functional Outcomes…  ................................ ..............................  28 
7. MANAGEMENT OF  ADVERSE  EXPERIENCES…  ................................ ...................  28 
7.1 Infection…  ................................ ................................ ................................ ........  29 
7.2 Other Harvest  Related  Issues…  ................................ ................................ ....... 29 
7.3 Psychological  Testing…  ................................ ................................ ...................  29 
7.4 Loss  of Confidentiality…  ................................ ................................ ...................  29 
8. CRITERIA FOR  INTERVENTION  DISCONTINUATION…  ................................ .........  29 
8.1 Description of  Subject Completion…  ................................ ................................  29 
8.2 Withdrawal of Individual Subjects…  ................................ ................................ . 30 
8.3 Withdrawal of Subject from th e Study Following  Adverse  Events…  .................  30 
8.4 Procedures for  Handling  Withdrawals…  ................................ ...........................  30 
8.5 Subject Replacement…  ................................ ................................ ....................  31 
9. STATISTICAL  CONSIDERATIONS…  ................................ ................................ ........  31 
9.1 Outcomes…  ................................ ................................ ................................ ...... 31 
9.1.1  Primary Safety Outcome…  ................................ ................................ . 31 
9.1.2  Secondary Objectives/Outcomes…  ................................ ....................  31 
9.2 Sample Size and  Accrual…  ................................ ................................ ..............  32 
10. DATA COLLECTION, SAFETY MONITORING, & ADVERSE EVENT REPORTING  32 
10.1 Record  Retention…  ................................ ................................ ........................  32 
10.2 Quality Assurance…  ................................ ................................ .......................  33 
10.3 Independent Medical  Monitor  (IMM)…  ................................ ...........................  33 
10.4 Medical Safety Monitor  (MSM)…  ................................ ................................ .... 34 
10.5 Data Safety and Monitoring  Board  (DSMB)…  ................................ ................  34 
10.6 Adverse Events Reporting…  ................................ ................................ ..........  34 
10.6.1  Overview…  ................................ ................................ .......................  34 
IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017  ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 5 of 49   10.6.2  Definitions… ................................ ................................ ......................  34 
10.6.2.1  Adverse Experience… ................................ .........................  34 
10.6.2.2  Disability…  ................................ ................................ ..........  34 
10.6.2.3  Life-Threatening  Adverse  Experience…  ..............................  34 
10.6.2.4  Serious Adverse Experience…  ................................ ...........  35 
10.6.2.5  Unexpected  Adverse Experience…  ................................ .... 35 
10.7 Recording  Adverse Events…  ................................ ................................ ..........  35 
10.7.1  Grading Criteria…  ................................ ................................ .............  35 
10.7.2  Attribution  Definitions…  ................................ ................................ .... 35 
10.8 Termination of the Cellular  Product Infusion…  ................................ ...............  36 
10.8.1  Stopping Rules…  ................................ ................................ ..............  36 
10.9 Communication and Reporting Serious  Adverse  Events…  .............................  36 
10.9.1  SAE Reporting  Timeline…  ................................ ................................  36 
11. HUMAN  SUBJECTS…  ................................ ................................ ...............................  37 
11.1 Institutional Review Board (IRB) Review and  Informed  Consent…  ................  37 
11.2 Subject Confidentiality… ................................ ................................ .................  37 
11.3 Study  Modifications/Discontinuation… ................................ ............................  37 
12. PUBLICATION OF  RESEARCH  FINDINGS…  ................................ ...........................  37 
13. REFERENCES…  ................................ ................................ ................................ ........  38 
14. APPENDIX A:  Table of  Study  Procedures  ................................ ................................  41 
15. APPENDIX B:  Table of Psychological and Functional  Outcome  Tests…  .................  43 
16. APPENDIX C:  DSMB  Charter…  ................................ ................................ ...............  44 
17. APPENDIX D :  Maternal Infectio us Disease  Testing…  ................................ ..............  49 
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 6 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   1. STUDY  OBJECTIVES  
 
This clinical trial studies autologous cell therapies in subjects with cerebral palsy (CP). 
We aim to compare the effects of two specific autologous cell therapies - bone marrow 
derived mononuclear cells (BMMNCs) versus human umbilical cord blood cells 
(hUCBs). Although both cellular products have an established safety record in children 
in the setting of bone marrow transplantation as well as a more limited experience with 
traumatic brain injury, th e safety of these cellular therapies in subjects with CP will be 
evaluated in this study.  This study will examine the following broad aims:  
 
1.1 Primary  Objective  
 
To determine if autologous cells using either BMMNCs or hUCBs are safe to 
administer in children with CP.  
Primary safety outcome measures:  
1. In-hospital infusion toxicity: pulmonary and hepatic function; new seizures, 
hemorrhagic lesions or ischemic lesions on  imaging.  
2. Long -term safety: development of new mass lesions or other pathological 
structural changes; worsening neurological  status.  
 
1.2 Secondary  Objective  
 
To determine if late functional outcomes are improved following the 
administration of autologous cells compared with subjects in the control group. 
Efficacy outcome measures:  
1. aMRI volumet ric white matter, grey matter, and CSF space volumes at Baseline, 
1 year and 2 years post -treatment. Detailed volumetric analysis of the corpus 
callosum and white matter tract such as the corticospinal tract will be measured 
(fractional anisotropy and mean  diffusivity) as well. Specific white matter tract 
analysis will be identified at baseline MRI and correlated with motor function 
studies as the primary lesion of interest. Total volumes and specific tract lesions 
will be analyzed and correlated with funct ional  outcomes.  
2. The following functional outcomes studies will be performed at baseline, 6 
months, 1 year after infusion, and 2 year after  infusion.  
a. Gross Motor Function  Measures  
b. Psychological Assessment  Batteries  
 
2. BACKGROUND  
 
2.1 Rationale for Initiating Protocol in  Children  
 
Cerebral palsy (CP) is a worldwide major health problem, caused by brain damage 
during pregnancy, delivery or the immediate postnatal period. According to the Centers 
for Disease Control (2011), cerebral palsy is the most common motor  disability in 
childhood, affecting approximately 1 in 303 8 -year-old children in the US. It is estimated 
that the average lifetime costs associated with cerebral palsy are approximately  
$921,000 per person. There are no effective treatments for CP. Our st em cell research 
team in neurological disorders, in addition to other research centers, has shown that  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 7 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   various types of cell therapies are safe and may enhance recovery from brain injuries 
such as stroke and TBI. The mechanisms underlying how certain cell therapies exert 
beneficial effects are likely multi -factorial and include the ability to modulate the 
inflammatory response after brain injury and to release factors that stimulate intrinsic 
brain repair processes such as neurogenesis, angiogenesis, and synaptogenesis. In 
fact, stem cells may adapt the profile of different repair pr omoting factors they secrete 
depending on the timing, type, and chronicity of the brain injury.  
 
2.2 Pre-Clinical  Data  
 
Cerebral Palsy and potential therapeutic time window: Stem cells and other types of cell 
therapies have been extensively studied in animal m odels of cerebral hypoxia -ischemia 
that simulate the conditions leading to cerebral palsy. Stem cells have been found in 
animal models of neonatal hypoxia to improve outcome when administered up to 10 
days after injury and up to 30 days after stroke in you ng adult rats. One month in a rat 
would translate to several years in humans. Furthermore, one of the principal brain cell 
types that regulates inflammation after brain injury are microglia, which recent studies 
have shown remain activated for years after brain injury in patients (Ramlackhansingh, 
2011). This chronic inflammatory response likely evolves over time and is associated 
with severe cognitive impairments. Our research has identified that some types of cell 
therapies target and modulate microglia t o reduce ongoing damage after brain injury.  
Overall, these data raise the possibility that stem cells may carry therapeutic potential in 
children chronically disabled with cerebral palsy.  
 
A large body of data indicates that both umbilical cord and bone ma rrow cells are 
attractive and highly promising sources of cell therapies for patients with brain injuries. 
The intravenous administration of mononuclear cells from umbilical cord and bone 
marrow has been shown in multiple animal models of cerebral ischemia  to improve 
neurological outcome (Meier, 2006). A pilot study has already shown that autologous 
cord blood is safe to administer in infants with acquired neurological disorders (Sun, 
2010). Pre -clinical and Phase 1 clinical studies have shown that BMMNC tr eatment for 
neurological injury reduces the neuro -inflammatory response and may preserve neural 
tissue.  The precise mechanism of action and potential time -window of treatment has 
not been defined. Data in rodent models of stroke suggests that the 30 -day t ime 
window may be the limit of potential effectiveness (de Vasconcelos dos Santos, 2010). 
In contrast, longitudinal imaging studies of patients after moderate TBI have shown 
progressive axonopathy, detectable by DTI in the regions of interest described abo ve 
(callosal volumes, FA, MD) from the 2 week post -injury time point to 6 months post - 
injury (Kumar, 2009). This progressive, ongoing evolution of the imaging findings 
suggests progressive demyelination and gliosis (Kraus, 2007). Preservation of white 
matter volumes and callosal volumes correlate positively and significantly with 
neurocognitive outcome. Given the safety findings in our pediatric Phase 1 study, we 
have designed this study to use an imaging based/ structural outcome variable as our 
primary m easure of efficacy.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 8 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   3. STUDY  DESIGN  
 
This is a randomized, blinded, placebo -controlled, cross -over study designed to treat 
CP in pediatric subjects with an IV infusion of autologous bone marrow mononuclear 
cells or autologous umbilical cord blood cells. A total of 30 subjects (15/arm) will be 
enrolled into the study. Subjects will be randomized 2:1 (treatment: sham). All subjects 
will return for follow -up at 6 months, 12 months, and 24 months post -treatment. At the 
12 months post -treatment vi sit, those subjects who originally received the sham will be 
offered the BMMNC or hUCB treatment (Figure  1). 
 
Figure 1.  
 
 
Thirty subjects will provide a preliminary assessment of potential SAEs with a 10 to 15% 
incidence that we would be able to detect wi th reasonable confidence. The sample size 
would also allow us to acquire point estimates of different events that we would use for 
a larger efficacy study. The sample size determination is based on the historical 
treatment effect size of 15% decrease in gr ay and white matter volumes.  Preservation  

ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 9 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   of this volume is based on the Phase 1 pediatric acute treatment of severe TBI using 
autologous bone marrow derived mononuclear cells as compared to historical control 
volumetric analyses by Wilde et al. (Wilde, E, et. al. 2005; Cox, C et al., 2011.)  
 
Drug/Biologic: A single dose of intravenously administered autologous BMMNC or 
hUCB.  The BMMNC dose will be 6X106  cells/kg body weight infused over 15 minutes 
at a 1 million cells/ml concentration. For the hUCB arm, the minimum acceptable dose 
will be 2X106cells/kg body weight based on rodent data (Lu, 2001), and the maximum 
allowable dose will be 10X106cells/kg. The target dose will be the maximum available 
dose within this range.  The bone marrow harve st, the hUCB reanimation, cell 
processing and product infusion will occur at Children’s Memorial Hermann Hospital and 
the Griffin Stem Cell  Laboratory.  
 
Placebo: 0.9% saline will be infused in an identical syringe over the same rate as if 
receiving a cell infusion, (See “Blinding of Placebo Infusion”).  
 
4. SELECTION AND ENROLLMENT OF  SUBJECTS  
 
4.1 Inclusion  Criteria  
1. Children  with diagnosis  of Cerebral  Palsy  (spastic  CP due to periventricular 
white matter damage or neonatal brain injury from perinatal stroke or intra- 
ventricular  hemorrhage)  
2. Gross Motor Function Classification Score level  II-V 
3. Ages 24 months to 10  years  
4. English speaking, if  verbal  
5. Ability to travel to Houston for treatment and  follow -up 
 
4.2 Exclusion  Criteria  
1. Known history  of: 
a. Intractable  seizures  
b. Traumatic brain  injury  
c. Genetic disorder (as demonstrated by newborn screening or genetic 
diagnostic  testing)  
d. Recently treated or current  infection  
e. Renal insufficiency or altered renal function (as defined by serum 
creatinine > 1.5 mg/dl at  screening)  
f. hepat ic disease or altered liver function (as defined by SGPT > 150 
U/L [non -contusion related], and/or T. Bilirubin >1.3 mg/dL at 
screening)  
g. HIV+ (as demonstrated by positive blood  test) 
h. Immunosuppression (as defined by WBC <3,000 cells/ml at  screening)  
i. Infectious related neurological  injury  
j. Sensitivity to Ethylene Oxide (EtO) [found in fumigants  and 
disinfectants]  
2. If Athetoid CP diagnosis, other etiologies such as degenerative, 
mitochondrial, and metabolic disorders must be excluded, and the outcome 
asse ssments must be able to be conducted to assess for potential  treatment 
effects  
ACT for CP Protoc ol V18  
Document Version Date: 18 OCT 2017  Page 10 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   3. Normal brain  MRI 
4. Evidence of acute illness at the time of infusion, such as, but not limited to, 
fever (temperature > 37.5 C), vomiting, diarrhea, wheezing or  crackles 
5. Progressing neurological disease (as defined by Batten  Disease, 
Leukodystrophies, Metabolic disorders, Mitochondrial disorders, 
Neurotransmitter  disorders)  
6. Microcephaly, macrocephaly, cortical malformations, genetic disorders of 
dysgenesis brain malformations due to infection or metabolic  disorders  
7. Pulmonary disease requiring ventilator  support  
8. If hUCB candidate, banked cord cells totaling <10  million/kg  
9. If hUCB candidate, any positive maternal infectious disease test (Hepatitis 
A/B, HIV 1, HIV 2,  HTLV 1, HTLV 2, and Syphilis), (r efer to Appendix  D) 
10. If hUCB candidate, cord blood sample  contamination  
11. Participation in a concurrent interventional research  study  
12. Unwillingness to return for follow -up visits  
13. Contraindications to brain MRI (metal implants, dental braces,  etc.) 
14. Any subject  that the investigators,  feel in their opinion  the study  intervention  is 
unlikely to benefit the subject will be a screen  failure  
15. Previous participating in other stem cell treatment or research  studies  
 
5. STUDY  INTER VENTIONS  
 
5.1 Bone Marrow  Arm 
 
5.1.1 Subject  Recruitment  
 
Fifteen pediatric subjects without banked umbilical cord blood meeting eligibility criteria 
will be enrolled into the bone marrow arm of the study. The parent(s)/LAR of potential 
subjects will contact the research team at The University of Texas Health Science 
Center at Houston. During this telephone call, an overview of the study and basic 
eligibility requirements will be reviewed. If eligibility requirements are met and the 
parent(s)/LAR willing to partic ipate, instructions will be provided on forwarding medical 
records to the research team for review and a consent and authorization for release of 
information (for contact with the subjects primary care provider [PCP]) will be sent to the 
parent(s)/LAR. Aft er receipt of medical records and contact with the PCP (if indicated) a 
telephone conference call will be scheduled with the parent(s)/LAR. During the call, 
study procedures and the informed consent document will be reviewed. Time will be 
given to answer q uestions. The parent(s)/LAR will not be pressured to make a decision 
on participation during the call.  Parent(s)/LAR choosing to participate in the study will 
be asked to return the signed informed consent in the postage paid envelope  provided.  
 
After rec eipt of the signed informed consent document, the parent(s)/LAR will be 
contacted by the research team to schedule the baseline/treatment visit. The 
parent(s)/LAR will be responsible for making all travel arrangements.  
 
5.1.2 Randomization  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 11 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   The randomization sequence will be computer -generated. The subject will be assigned 
to the treatment or control arm in a 2 :1 ratio using sequentially numbered, opaque, 
sealed envelopes prepared by a member of the Center for Surgical Trials and Evidence - 
based Practice (C -STEP) not involved in the clinical trial.  
 
5.1.3 Baseline Visit and Bone Marrow (Placebo)  Harvest/Infusion  
 
The outpatient baseline visit will be conducted in the Pediatric Outpatient Surgery Clinic. 
At the baseline outpatient visit, the signed informed consent document will be reviewed 
with the parent(s)/LAR and assent obtained from the subjects if they are able to  do so. 
During this 1 day outpatient visit, subjects will undergo baseline assessments including 
physical and neurological exams, laboratory tests, chest radiograph, oxygen saturation 
monitoring, psychological testing, and quality of life measurements. The  neuroexam will 
be videotaped for blinded assessments of dystonia using standardized scales validated 
for use on children with CP.  The research team will review information from the 
baseline assessments to ensure the subject remains eligible for participa tion and that 
there are no unanticipated reasons to exclude the subject, (such as recent  infection).  
After completing the outpatient baseline visit assessments, eligible subjects will be 
admitted to a Children’s Memorial Hermann Hospital pediatric unit.  
 
The bone marrow harvest will be performed under sedation (Propofol) and local 
anesthetic before or immediately after the baseline DTMRI. The subject may be log - 
rolled to a 45 degree angle for access to the posterior iliac crest or remain supine to 
access a nterior iliac crest. The bone marrow harvest will be performed under aseptic 
conditions. The bone marrow harvest is performed using either an 11 -gauge needle or 
15-gauge needle inserted into the iliac crest(s). Approximately 2 – 3 mL (< 40 kg body 
weight) to 5 – 6 mL (> 40 kg body weight) of bone marrow aspirate will be obtained and 
transferred in as sterile manner in a validated Coleman® cooler at ambient temperature 
to the Griffin Stem Cell Laboratory (GSCL).  An additional blood sample will be drawn 
for infectious disease testing that includes HIV 1 and II, Hepatitis B and C, HTLV 1 and 
II, Syphilis, CMV, West Nile Virus, and ABO blood type. Transportation, processing, 
assessing and quality assurance at GSCL are described in the Chemistry & 
Manufacturing section of the IND. Approximately 6 – 7 hours after bone marrow 
aspiration, subjects will receive the BMMNC via peripheral or central intravenous 
infusion in a time not to exceed 30 minutes. The product will be infused within 30 
minutes of receipt at Child ren’s Memorial Hermann Hospital, and will remain in the 
cooler until ready for infusion.  
 
5.1.4 Sham Harvest  Procedure  
 
A 3mL sample of peripheral blood will be collected immediately prior to the harvest 
sham procedure. The sham harvest will be performed under s edation (Propofol) with a 
local anesthetic used at the site. The subject may be log -rolled to a 45 degree angle for 
access to the posterior iliac crest or remain supine to access the anterior iliac crest. An 
11-gauge or 15 -gauge needle will be used to punc ture through the skin, but will not be 
inserted into the iliac bone. The puncture site will then be steri -stripped closed and 
covered with an identical external bandage. No bone marrow aspiration or harvest will  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 12 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   take place. The clinical care providers will not be allowed to observe the harvest and 
will not be informed of the assigned group.  
 
Approximately 6 – 7 hours after the sham bone marrow aspiration, subjects will receive 
a placebo saline infusion via peripheral or central intravenous infusion in a time not to 
exceed 30 minutes. Identical to the BMMNC infusion, the placebo will be  infused within 
30 minutes of receipt at Children’s Memorial Hermann Hospital, and will remain in the 
cooler until ready for infusion.  
 
5.1.5 Schedule of Vital Signs during Harvest &  Infusion  
1. Immediately prior to bone marrow or sham  harvest  
2. During harvest: vital  signs continually monitored & recorded every 5  minutes  
3. Post-harvest: q 15 minutes x 4 (1st hour), q 30 minutes x 4 (next 2 hours), and 
then every hour until the  infusion  
4. Immediately prior to  infusion  
5. During infusion: vital signs continually monitored & recorded every 5  minutes  
6. Post Infusion: q 15 minutes x 4 (1st hour), q 30 minutes x 4 (next 2 hours), 
q 1 hour x 4 (next 4 hours), and then every 4 hours  thereafter.  
 
5.1.6 BMMNC  Dosing  
 
Our target dose is 6×106 BMMNC/Kg body weight. The target dose is based on pre- 
clinical animal data where cells were administered locally (intramyocardial) in a clinical 
protocol for patients with congestive heart failure (cell harvest of > 30×106 cells or 
approximately 0.4×106 cells/Kg body weight from a total of 50 mL of bone marrow 
harvested) (Perin et al. , 2003), and our pediatric Phase I clinical trial using a similar 
protocol (Cox et al., 2011). In other studies, rat BMMNCs were isolated and 2×106 
cells/350gm were administered intravenously (Lu et al. , 2001).  
 
GSCL estimate d that over 1×108 cells could be obtained from the proposed bone 
marrow harvest, and this was confirmed in our Phase I Trial. The cells will then be re - 
suspended to a 1 mL/Kg final volume.  Below is a sample dosing calculation:  
 
70Kg subject at the dose t arget:  
Total Dose= Subject weight (Kg) X 6×106 cells 
Dose required= 70Kg X 6×106 cells = 420×106 
Yield expected= 350 mL bone marrow to yield 7×108 cells or 700×106 cells.  
 
Smaller harvest yields may necessitate reducing our dose target. If the yield is bel ow 
the target, then the upper doses may be impractical and we will use/infuse the 
maximum obtainable dose for each subject. Data will be analyzed as such. It will not 
be a protocol deviation if the dose target is not reached.  
 
5.1.7 Post-Infusion  Period  
 
The day  following infusion will be considered Post -Infusion Day 1, regardless of what 
time of the day the infusion was given. Post -infusion monitoring will include 
hemodynamics, infusion related toxicities (pulmonary, hepatic, and renal lab indices),  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 13 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   and neurologic complications. Laboratory tests will include a CBC with differential, 
chemistry panel, hepatic function panel, and coagulation panel. As part of the 
pulmonary monitoring a chest x -ray will be performed and blood -oxygen saturation will 
be m onitored by finger oximeter. In the event of pulmonary dysfunction, standard 
supportive therapy will be given. The research team will review the first 24 hours of 
post-infusion monitoring for AE/SAE’s and determine if the subject is eligible for 
discharge home. Any serious adverse event as described in the Statistical 
Considerations section will be reported immediately and referred to the DSMB and 
evaluated for potential relationship to the protocol.  
 
Prior to discharge, the parent(s)/LAR will be given deta iled instructions regarding signs 
and symptoms of infection such as fever, malaise, and chills and told to check the 
subject’s body temperature twice daily for three weeks after discharge (through post - 
infusion day 21). Parents(s)/LAR will be instructed t o immediately report neurological 
changes or seizure activity to the research team. A CBC and basic chemistry panel will 
be obtained 21 days post -infusion (+/ - 7 days). Parent(s)/LAR will be given the option of 
having the lab tests performed by their PCP o r, for local families, here at UTHealth. The 
research team will have daily contact with the parent(s)/LAR through post -infusion day  
21. Monitoring information will be recorded on the case report form and any reports of 
abnormalities will be relayed to the study PI/Co PI immediately. If indicated, the 
parent(s)/LAR will be instructed to have the subject seen be their PCP for further 
evaluation. Local families may opt to be seen by the research team for adverse events 
evaluation.  
 
After discharge, the subject ’s PCP will be given discharge summary information. The 
PCP will be asked to consult with the study PI on any AE/SAE’s post -infusion to ensure 
that appropriate therapy/treatment is given to the subject.  
 
5.1.8 Cross -Over and Follow -Up Visits  
 
As part of the tria l, the subjects will return to The University of Texas Health Science 
Center at Houston for 3 follow -up visits: 6 months (+/ - 14 days), 1 year post -treatment 
(+/- 21 days), and 2 years post -treatment (+/ - 21 days). Each visit will take place over 
1-2 days in which the subject will undergo outpatient assessments that include physical 
and videotaped neurological exams, laboratory tests, chest radiograph, oxygen  
saturation monitoring, psychological testing, and quality of life measures. DTMRI will be 
performed  at the 1 and 2 year post -treatment visits.  
 
Prior to the 1 year follow -up visit, the treatment blind will be broken and the 
parent(s)/LAR notified. At this time, the parent(s) of children in the placebo group may 
choose to have their child admitted to the  Children’s Memorial Hermann Hospital 
pediatric unit for bone marrow harvest and infusion. All procedures will be followed in 
the same manner as was done for the Treatment Group.  
 
5.1.9 Blinding of Placebo  Infusion  
 
To prevent distinguishing between placebo and cellular products, a 3 mL sample of 
peripheral blood will be collected immediately prior to sham harvest in addition to the  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 14 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   standard blood samples collected for QA and infectious disease testing. This blood will 
be anti -coagulated with acid c itrate dextrose and delivered to the cell processing 
laboratory.  The 3 mL blood sample will be added to 30 mL of 0.9% saline containing 
5% volume/volume human serum albumin and loaded in a sterile syringe identical to the 
one used for the BMMNC cellular p roduct. Sterility QC assays will be performed 
including gram stain, 14 day aerobic and anaerobic cultures and 28 day fungal cultures. 
A negative gram stain result will be required for release of the placebo.  The final 
product will be labeled identically t o the cellular product. The placebo will then be 
transported to the site of administration in the same manner as the cellular therapy 
product and infused at the same rate used to infuse cellular  product.  
 
5.2 Cord Blood  Arm 
 
5.2.1 hUCB Collection, Processing and  Storage  
 
We will only recruit pediatric subjects who have their hUCB stored with Cord Blood 
Registry® (CBR) (CBR Systems, Inc., San Bruno, CA) and meet the study entry criteria. 
CBR is a private cord blood bank accredited by the American Association of Blo od 
Banks (AABB) with an inventory of over 400,000 banked hUCB samples.  Their 
stringent laboratory processes, record keeping and quality control are designed to meet 
all federal (FDA) and state guidelines and regulations. CBR is licensed by the states of 
New York, Maryland, New Jersey, California, and Illinois who have their own set of strict 
regulations for stem cell banks. The CBR laboratory is also CLIA  certified.  
 
5.2.2 CBR hUCB Sample  Quality  
 
CBR collection methods are virtually free of microbial and fungal  contamination as 98% 
of units are sterile upon testing (Harris, 2008) CBR has extensive experience with Ficoll - 
Hypaque and AXP processing and is able to attain high stem cell recovery rates as 
assessed by MNC and TNC recovery rates following processing. Ficoll -Hypaque 
processing recovers 98% of the MNC fraction (Harris, 2002), while AXP processing 
recovers 98.7% of the MNC fraction and 96.2% of the TNC fraction (Rosenthal, 2008).  
CBR has provided 86 hUCB samples for use in transplant to 26 different trans plant 
centers with an average post -thaw viability of >90% based on measures conducted at 
the transplant centers and all hUCB units released have tested viable (Harris, 2008).  
 
5.2.3 Subject  Recruitment  
 
Fifteen pediatric subjects who have their umbilical cord bl ood banked with CBR and 
meet study criteria will be enrolled into the cord blood study arm. The parent(s)/LAR of 
potential subjects will contact CBR. After receiving permission to release the subject’s 
contact information, CBR will then relay the contact i nformation to the research team, 
who will then contact the parent(s). During this telephone call, an overview of the study 
and basic eligibility requirements will be reviewed. If eligibility requirements are met and 
the parent(s)/LAR willing to participate , instructions will be provided on forwarding 
medical records to the research team for review and a consent and authorization for 
release of information (for contact with the subjects primary care provider [PCP]) will be 
sent to the parent(s)/LAR.  After r eceipt of medical records and contact with the PCP (if  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 15 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   indicated) a telephone conference call will be scheduled with the parent(s)/LAR. During 
the call, study procedures and the informed consent document will be reviewed. Time 
will be given t o answer questions. The parent(s)/LAR will not be pressured to make a 
decision on participation during the call.  Families choosing to participate in the study 
will be asked to return the signed informed consent in the postage paid envelope 
provided.  
 
After receipt of the signed informed consent document, CBR will be notified to release 
cord blood information to the research team. The parent(s)/LAR will be contacted by 
the research team to schedule the baseline/treatment visit. The parent(s)/LAR will be 
responsible for making their travel arrangements.  
 
Approximately 4 – 6 weeks prior to the scheduled procedure date, the subject will have 
the infectious disease testing for HIV 1 and II, Hepatitis B and C, HTLV 1 and II, 
Syphilis, CMV, and West Nile Virus.  An additional 8 – 10 mL of blood will be collected 
at this time and shipped overnight to a Cell and Gene Therapy (CAGT) lab in Houston 
for HLA testing. All lab results will be sent to the research team for review prior to the 
baseline/treatment visit. If t he subject has a positive HIV, Hepatitis B, or C test; they will 
be excluded from the  study.  
 
5.2.4 Maternal Infectious Disease  Testing  
 
CBR routinely collects a maternal blood sample at the time of delivery for infectious 
disease marker (IDM) testing. The maternal IDM results (if available) will be released to 
the research team along with the cord blood sterility and cell count information after 
informed consent has been obtained and CBR has obtained permission from the 
parent(s)(s).  The infectious disease  tests include: Human Immunodeficiency Virus 
(HIV) type 1, HIV type 2, Hepatitis B virus, Hepatitis C virus, Human T -cell 
lymphotrophic virus (HTLV) type I, HTLV type II, and Syphilis. If any maternal infectious 
disease markers were positive at the time of  the collection the cord blood will not be 
used, and the subject will not be eligible, ( refer to Appendix D ).  Per CBR, less than 
10% of cord blood collections do not have the maternal IDM testing performed. In the 
event that a subject meets criteria for s tudy entry, but CBR does not have the maternal 
IDM results, the parent(s) can submit IDM results that were performed during the 
pregnancy, for instance as part of the prenatal labs or performed during the hospital 
admission for delivery. If the IDM tests w ere not completed during the pregnancy, the 
mother will be required to have IDM testing completed at her expense and lab results 
submitted to the PI. If any of the results of the maternal IDM tests are positive, the 
subject will be ineligible. There is a c hance the mother may not have been positive 
during the pregnancy and the time of delivery; however, we have chosen to err on the 
side of caution. It is also important to note, that maternal testing is not required under 
federal regulations for autologous c ord blood infusions {CFR 21.1271.90}; however, we 
have chosen to require maternal infectious disease testing in this  protocol.  
 
5.2.5 Randomization  
 
Subjects in the hUCB group will be randomized after receipt of subject and maternal 
infectious disease results an d CBR cord blood information on viability and cell count.  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 16 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Subjects found ineligible for cord blood infusion due to low or non -viable cell count or 
contamination will be offered the opportunity to enroll in the other treatment arm of the 
study  if the enrollment limit for the BMMNC group has not already been met.  
The randomization sequence will be computer -generated. The subject will be assigned 
to the treatment or control arm in a 2:1 ratio using sequentially numbered, opaque, 
sealed envelopes prepared by a member of the Center for Surgical Trials and Evidence - 
based Practice (C -STEP) not involved in the clinical trial.  
 
5.2.6 Shipping of Cord  Blood  
 
For subjects randomized to receive hUCB at the baseline visit, the GSCL will request a 
segment of the subject’s banked cord blood sample from CBR. The subject’s HLA lab 
results will be compared to the cord blood sample for HLA type (6/6 match).  
Additionally, the cord blood segment will be tested for viability and cell count. Results 
from the HLA typing wil l be faxed to CBR to confirm the subject’s identity. CBR will ship 
the frozen cord blood to the GSCL 7 – 14 days prior to the scheduled procedure, where 
it will be kept frozen until the morning of infusion. It is important to note that once cord 
blood has been shipped from CBR it cannot be returned. If the subject is randomized to 
the placebo group, cord blood unit will NOT be shipped. All HLA lab results will remain 
on record for reference at the 1 year cross -over visit (if indicated).  
 
5.2.7 Baseline Visit and Cord Blood (Placebo)  Infusion  
 
The outpatient baseline visit will be conducted in the Pediatric Outpatient Surgery Clinic. 
At the baseline outpatient visit, the signed informed consent document will be reviewed 
with the parent(s)/LAR and assent obtained from the subjects if they are able to do so. 
During this 1 day outpatient visit, subjects will undergo baseline assessments including 
physical and neurological exams, laboratory tests, chest radiograph, oxygen saturation 
monitoring, psychological testing, and quality of life measurements. The neuroexam will 
be videotaped for blinded assessments of dystonia using standardized scales validated 
for use on children with CP.  The research team will review information from the 
baseline assessments to ensure the s ubject remains eligible for participation and that 
there are no unanticipated reasons to exclude the subject, (such as recent  infection).  
After completing the outpatient baseline visit assessments, eligible subjects will be 
admitted to a Children’s Memoria l Hermann Hospital pediatric unit.  
 
The baseline DTMRI will be performed as soon as possible following early AM 
admission with the cord blood/placebo infusion immediately before or after the DTMRI. 
For subjects receiving cord blood, the GSCL will thaw, pro cess, and transport the cord 
blood prior to infusion. For subjects randomized to the placebo group, the GSCL will 
prepare a placebo infusion according to the procedure described previously for the bone 
marrow placebo arm, with the exception that it will be  loaded in a sterile transfer pack 
identical to the one used for hUCB cellular product, and the infusion medium will be 
Dextran 40 containing 5% volume/volume human serum albumin. The pack will be 
labeled in the manner described in the standard operating p rocedure (identically to the 
labeling used for the cellular product). The placebo will be transported to the site of 
administration in the same manner as the cellular therapy product. The infusion rate will 
be approximately 5cc/minute for both groups.  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 17 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   5.2.8 Schedule of Vital Signs during and  Post-Infusion  
1. Immediately prior to  infusion  
2. During infusion: vital signs continually monitored & recorded every 5  minutes  
3. Post Infusion: q 15 minutes x 4 (1st hour), q 30 minutes x 4 (next 2 hours), q 1 
hour x 4 (next 4 hours), and then every 4 hours  thereafter.  
 
5.2.9 Post-Infusion  Period  
 
The day following infusion will be considered Post -Infusion Day 1, regardless of what 
time of the day the infusion was given. Post -infusion monitoring will include 
hemodynamics, infusion related toxicities (pulmonary, hepatic, and renal lab indices), 
and neurologic complications. Laboratory tests will include a CBC with differential, 
chemistry panel, hepatic function panel, and coagulation panel. As part of the 
pulmo nary monitoring a chest x -ray will be performed and blood -oxygen saturation will 
be monitored by finger oximeter. In the event of pulmonary dysfunction, standard 
supportive therapy will be given. The research team will review the first 24 hours of 
post-infusion monitoring for AE/SAE’s and determine if the subject is eligible for 
discharge home. Any serious adverse event as described in the Statistical 
Considerations section will be reported immediately and referred to the DSMB and 
evaluated for potential re lationship to the protocol.  
 
Prior to discharge, the parent(s)/LAR will be given detailed instructions regarding signs 
and symptoms of infection such as fever, malaise, and chills and told to check the 
subject’s body temperature twice daily for three weeks  after discharge (through post - 
infusion day 21). Parents(s)/LAR will be instructed to immediately report neurological 
changes or seizure activity to the research team. A CBC and basic chemistry panel will 
be obtained 21 days post -infusion (+/ - 7 days). Pa rent(s)/LAR will be given the option of 
having the lab tests performed by their PCP or, for local families, here at UTHealth. The 
research team will have daily contact with the parent(s)/LAR through post -infusion day  
21. Monitoring information will be recorded on the case report form and any reports of 
abnormalities will be relayed to the study PI/Co PI immediately. If indicated, the 
parent(s)/LAR will be instructed to have the subject seen be their PCP for further 
evaluation. Local families may opt to be seen by the research team for adverse events 
evaluation.  
 
After discharge, the subject’s PCP will be given discharge summary information. The 
PCP will be asked to consult with the study PI on any AE/SAE’s post -infusion to ensure 
that appropriate therapy /treatment is given to the subject.  
 
5.2.10  Cross -Over and Follow -Up Visits  
 
As part of the trial, the subjects will return to The University of Texas Health Science 
Center at Houston for 3 follow -up visits: 6 months (+/ - 14 days), 1 year post -treatment 
(+/- 21 days), and 2 years post -treatment (+/ - 21 days). Each visit will take place over 
1-2 days, and the subject will undergo outpatient assessments which include physical 
and videotaped neurological exams, laboratory tests, chest radiograph, oxygen  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 18 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   saturation monitoring, psychological testing, and quality of life measures. DTMRI will be 
performed at the 1 and 2 year post -treatment visits.  
 
Prior to scheduling the 1 year follow -up visit, the treatment blind will be broken and the 
parent(s) notified.  At this time, the parent(s) of children in the placebo group may 
choose to have their child admitted to the Children’s Memorial Hermann Hospital 
Pediatric ICU/MICU for cord blood cell infusion. If the subject’s parent(s) agrees to the 
cord blood infusion,  the study coordinator will notify the Director of GSCL of the 
scheduled visit date. The Director will then request that the cord blood be shipped from 
CBR.  The frozen cord blood unit will be shipped overnight to the GSCL 7 – 14 days 
prior to the schedule d procedure. The cord blood will be kept frozen until the morning of 
the infusion. All procedures will be followed in the same manner as was done for the 
Treatment Group.  
 
5.3 Handling of Cord Blood/BMMNC  Interventions  
 
Transportation, processing, assessing an d quality assurance at GSCL are described in 
the Chemistry & Manufacturing section of the IND ||. 
 
5.4 Pre-Infusion Medications (All  Groups)  
 
Thirty minutes prior to the infusion, all subjects (regardless of treatment assignment) will 
receive intravenous Benadryl 0.5mg/Kg and Solu -Medrol 0.5mg/Kg. Additionally, the 
following medications will be ordered prior to the infusion and kept at the subjects’ 
bedside: Benadryl 50 mg for injection, Epinephrine 1:10,000 – 10 mL for injection and 
Hydrocortisone 100 mg for injection (or Solu -Medrol 0.5mg/Kg).  
 
5.5 Prohibited  Interventions  
 
Subjects may not be enrolled in other interventional research protocols while 
participating in this study.  
 
6. CLINICAL AND LABORARTORY  EVALUATIONS  
 
6.1 Schedule of Events (See Appendix  A) 
 
6.2 Infusion Toxicity  Complications  
 
6.2.1 Hemodynamic  Instability  
 
Subjects will be admitted to the pediatric at Children’s Memorial Hermann Hospital 
following the baseline outpatient visit and will be monitored continuously until discharge 
as described in previous  sections. A primary concern is the precipitation of 
hemodynamic instability associated with infusion -related toxicities of cellular product 
transplant. It has been reported that hypotension, hypertension and bradycardia can 
occur from transplantation of c ellular product that has been cryopreserved in 
dimethylsulfoxide (DMSO) and RBC depletion. To minimize the effect of these, our 
hUCB product will be washed according to Standard Operating Procedures prior to  
ACT for CP Protocol V18  
Document Versio n Date: 18 OCT 2017  Page 19 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   infusion. However, it is possible that some quantity of DMSO will remain. To minimize 
the risk of hemodynamic instability, maintenance + an additional 10 – 40mL/Kg 
intravenous 0.9% saline volume replacement will occur concomitantly with the cellular 
product infusion. Blood pressure elevati on will be defined as an increment of more than 
20% from the baseline value at the beginning of the infusion (Konuma, 2008). An 
adverse event will be defined as a sustained (> 10 minutes) >20% decrease in MAP. 
Transient decreases in the mean arterial press ure (MAP) that respond to fluid infusion 
or inotropes will not be considered adverse events.  Prolongation of capillary refill 
greater than 2 seconds from baseline as well as a greater than 20% change in heart 
rate during the procedure will prompt an evalu ation as to the etiology of the change in 
hemodynamic status. Bradycardia, defined by a sustained reduction in heart rate, less 
than 40beats/min, that is unresponsive to intravenous fluid or inotrope support will be 
considered an adverse event. Restoration  of hemodynamics to baseline will allow 
resumption of infusion. Inability to transfuse will preclude further participation in the 
study, though the subject will be followed for data collection per protocol.  
 
6.2.2 Pulmonary  Complications  
 
A concern exists regarding the systemic infusion of leukocytes in a concentrated 
manner. Theoretically, activated monocytes could function to enhance 
polymorphonuclear leukocytes (PMN) migration into the lung, as the lung is the primary 
“first pass” filter for intravenous infusion of any cellular product. PMN mediated organ 
injury typically occurs over a 6 – 24 hour time frame. Based on this, chest radiographs 
will be performed and evaluated at Baseline and on Post -Infusion Day 1. Additionally, 
blood -oxygen saturation will be monitored by finger pulse oximetery (SpO 2). Moderate 
respiratory dysfunction within the first 24 hours post – infusion will be considered an 
adverse event but will not warrant stopping the trial unless recommended by the DSMB. 
In the event of pulmonary dysfunction, standard supportive therapy will be given.  
Pulmonary symptoms/events corresponding to the CTCAE v4.0 Grade 3 will trigger the 
stopping rules described in section 10.  
 
6.2.3 Hepatic  Injury  
 
The reticuloendothelial system can sequester immature blood elements, theoretically 
resulting in hepatic injury. An acute elevation of the AST/ALT hepatic enzymes > 900 
U/dL in the first 24 hours post – infusion will trigger the stopping rules. This level is 
corresponds to the CTCAE v4.0 Grade 4 adverse event. It i s unlikely that “end vessel” 
microthrombosis would occur in the liver due to the dual blood supply of the liver and 
the lung is the first pass organ.  
 
6.2.4 Renal  Complications  
 
DMSO induces hemolysis of contaminating red blood cells during the hUCB storage 
and may also induce in vivo hemolysis and ultimately pigment nephropathy (Smith, 
1987). To minimize the effect of these, our hUCB product will be washed according to 
Standard Operating Procedures prior to infusion. Though unlikely, it is possible that 
some qua ntity of DMSO will remain which could cause toxicity. Renal function/events 
corresponding to the CTCAE v4.0 Grade 3 will trigger the stopping rules.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 20 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   6.2.5 Neurologic  Complications  
 
The subject’s acute neurologic status will be monitored hourly unti l discharged. Hourly 
GCS, pupillary size/reactivity, motor/sensory evaluation of extremities, and any seizure 
activity will be recorded from time of infusion to discharge. Grade 3 – 5 central nervous 
system event as defined in the NCI CTCAE v4.0 occurring within 12 hours of cellular 
product infusion will trigger the stopping rules. Other changes temporally related to 
cellular product infusion (those events occurring within 12 hours of infusion) will be 
considered associated with the protocol and recorded as  an adverse event.  
 
6.3 Psychological & Functional Outcome Assessment  Tests  
 
The following tests will be performed at baseline and all follow -up visits for children who 
have the visual, motor, and language abilities needed to complete the assessment 
tasks, (note table in Appendix B).  
 
6.3.1 Motor  Functioning  
 
The Gross Motor Fine Motor - 88 Scale (GMFM -88) is an 88 -item standardized, 
observation -based assessment of children's gross and fine motor abilities. It was 
designed for motor assessment of children with cer ebral palsy. Administration time is 
45-60 minutes.  
 
6.3.2 Quality of  Life 
 
The parent(s) proxy version of the Cerebral Palsy Quality of Life Questionnaire (CP 
QOL) is measure of health related quality of life for children ages 4 through 12 years. 
The 66 -item que stionnaire assesses QOL across seven domains (1) social well -being 
and acceptance; (2) feelings about functioning; (3) participation and physical health; (4) 
emotional well -being; (5) access to services; (6) pain and feeling about disability; and  
(7) paren t(s) health.  Completion time is approximately 30 -45 minutes.  The 
questionnaire may be completed by telephone at a time convenient for Parent(s) prior to 
the study visit.  
 
6.3.3 Adaptive Behavior  Functioning  
 
The Vineland Adaptive Behavior Scales – 2nd Edition (VABS -2), is a parent(s)/caregiver 
report measure that provides information regarding a child's adaptive behavior/daily 
living skills. The VABS -2 is appropriate for children from birth through age 10 and 
produces standard scores in the following domains: C ommunication, Daily Living Skills, 
Socialization, and Motor Skills. The measure takes between 25 and 90 minutes to 
complete.  
 
The Pediatric Evaluation of Disability Inventory is a parent -report measure of adaptive 
functioning that is designed specifically for children with functional impairments and is 
sensitive to small changes in adaptive skills at the low end of the functioning spectrum.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 21 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   6.3.4 Visual -Spatial  Processing  
 
The Motor Free Visual Perception Test - 3rd Edition (MVPT -3) will be administered to 
obtain information regarding visual perceptual abilities among children ages 4 -10 years 
old across 5 domains: (1) spatial relationship, (2) visual closure, (3) visual 
discrimination, (4) visual memory, and (5) figure ground. Standard scores are produced 
and administration time is approximately 25 minutes.  
 
6.3.5 Learning/Memory  
 
The Narrative Memory subtest fro m the NEPSY -II, a developmental psychological 
battery for children, will be administered to obtain information regarding memory and 
learning ability: The Narrative Memory subtest can be administered to participants ages 
3-10 years old and produces a standa rd score that indicates memory for organized 
verbal material under free recall, cued recall, and recognition conditions. Administration 
time will take approximately 10 minutes.  
 
6.3.6 Expressive and Receptive  Vocabulary  
 
The Peabody Picture Vocabulary Test – 4th Edition (PPVT -4) produces a standard 
score indicating subjects' receptive one word vocabulary and will be administered to 
children ages 2.6 -10 years old. Responses can be indicated either verbally or pointing 
to a picture and so is appropriate for all p articipants, regardless of motor abilities.  
Administration time is approximately 15 minutes. The PPVT -4 score is often considered 
an appropriate indication of general cognitive functioning. The Expressive Vocabulary 
Test - 2nd Edition (EVT -2) will provide a standard score indicating subjects' expressive 
one word vocabulary.  Responses are provided verbally and so the test is appropriate 
for all children (ages 2.6 -10 years old), regardless of motor abilities. Administration time 
is approximately 15 minutes.  
 
6.4 MRI Evaluation  
 
6.4.1 CP Neuroimaging  
 
CP is a clinical diagnosis inclusive of a heterogeneous group of patients with differing 
patterns of neurological subtype (spastic -quadriplegic –hemiplegic –diplegic; 
ataxic/hypotonic; dyskinetic), severity (GMFCS level),  type of lesion(s), location of 
lesion(s), and functional status (ambulatory/non -ambulatory). Although the 
pathogenesis of CP is still poorly understood, advanced neuroimaging studies have led 
investigators to the identification of some cerebral abnormalit ies frequently observed in 
young children with a diagnosis of CP (Towsley et al., 2011). Such cerebral anomalies 
include the following: (1) periventricular white matter damage, (2) diffuse gray matter 
damage, (3) cerebral vascular accident, and (4) malform ation of cortical development. 
Due to heterogeneity in etiological bases of primary and secondary insults to the 
developing brain which manifest as different cerebral anomalies, new interdisciplinary 
studies of CP are needed to evaluate cerebral anomalies in relation to neurological 
subtype and identifiable lesion types (and locations).  Such an interdisciplinary 
approach has high potential to identify quantitative measures of brain structure with  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 22 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   
prognostic value as they explain neurological subtype, severity, and functional status. 
Such information is vital for the development of interventional strategies and predicting 
response to different types of interventions given the “profile” of each individual patient. 
Some neuroimaging studies have reported specific regions which are highly susceptible 
to being compromised in CP ( Hoon et al., 2005; Hoon et al., 2009; Panigrahy et 
al.,2005; Son et al., 2007; Son et al.,2009; Thomas et al., 2005; Yoshida et al., 2010).  
By conducting an objective analysis which integrates quantitative measures of 
microstructural integrity (in white matter pa thways) and quantitative measures of 
associated cortical/subcortical atrophy (in gray matter), the proposed study has the 
potential to identify neural systems compromised by CP and subsequently monitor 
response to treatment in a system -specific fashion.  
 
Based on published literature (Towsley et al., 2011; Yoshida et al., 2011), spastic CP is 
expected to be predominately related to evidence of periventricular leukomalacia (PVL) 
or diffuse gray matter injury (GFCMS levels IV -V); or a cerebral vascular accide nt. In 
contrast, ataxic CP is expected to be related to white matter volume loss and increased 
mean diffusivity in deep gray matter structures (e.g. putamen, globus pallidum, and 
thalamus).  
WM ROIs compromised in children with CP (Yoshida et al., 2011): 
Anterior Limb of the Internal Capsule (ALIC) – dyskinetic = ↓ FA 
Posterior Limb of the Internal Capsule (PLIC) – spastic & dyskinetic = ↓ FA 
External Capsule (EC)Posterior thalamic radiation – spastic & dyskinetic = ↓ FA 
CC_genu – dyskinetic = ↓ FA 
CC_splen ium – spastic & dyskinetic =  ↓ FA Figure  3. 
CC_body – spastic = ↓ FA 
Cingulum Bundle – dyskinetic = ↓ FA 
CST – spastic & dyskinetic = ↓ FA 
SLF – spastic & dyskinetic = ↓ FA 
ILF – spastic & dyskinetic = ↓ FA 
Thalamocortical pathways – spastic = ↓ FA 
GM ROIs  compromised in children with CP:  
Basal ganglia = ↓ volume 
Thalamus = ↓ volume 
Precentral Gyrus = ↓ volume 
Postcentral Gyrus = ↓ volume 
Paracentral lobule = ↓ volume  
 
6.4.2 MRI Acquisition and  Analyses  
 
The primary goal of acquiring whole brain MRI data is twofold: (1) to quantitatively 
assess macro - and micro -structural properties of GM and WM regions in two groups 
(+BMMNC / -BMMNC) using state -of-the-art neuroimaging acquisition/analysis methods 
and (2) to investigate macro - and micro -structural correlates  of behavior in terms of 
cognitive performance and underlying neuropathology in a hypothesis – driven manner.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 23 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   To accomplish these objectives, the MRI data needs to be collected using two different, 
yet complementary modalities of MRI: (1) hig h-resolution anatomical MRI (aMRI) and  
(2) diffusion tensor imaging (DTI). While data from both modalities is easily acquired in 
the same imaging session, the total scan time needs to be kept to the minimum 
necessary to achieve the specific aims within a t imeframe generally well -tolerated by 
young children (e.g. ~30min). An earlier version of our proposed MRI protocol has been 
successfully completed by more than 400 children between the ages of 6 and 18 years 
old at our Imaging Research Facility during the course of ongoing NIH -supported 
studies involving diverse study populations including SBM, TBI, Learning Disabilities, 
and, typically -developing healthy controls.  The following five pulse sequences 
constitute a complete imaging session: (1) conventional l ocalizer/scout, (2) 3D isotropic 
T1-weighted MPRAGE, (3) 3D isotropic T2 -weighted TSE, (4) 32 -direction single -shot 
spin-echo diffusion sensitized echo -planar (DTI -32dir), and (5) 3D -FLAIR. 
Morphometric, diffusion tensor tractography, and DTI -derived metri cs of microstructural 
properties of GM and WM (e.g. MD, FA) can all be performed in about 20 minutes. 
Parameters for each sequence are listed below in Figure  4. 
 
Figure 4.  
 
 
6.4.3 Anatomical MRI  Analysis  
 
All scans will be analyzed blind to diagnosis, age, and gender. Datasets with significant 
motion artifact during acquisition will have been re -acquired in the same imaging 
session based on real -time evaluation of imaging data and decisions made by Dr.  

ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 24 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Juranek. See figures 5a/b for example of signi ficant motion artifact subject to re - 
acquisition.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 25 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Figure 5.  
A B 
  
 
Figure 5A/B: Examples of T1 -weighted image acquisition data from children without 
head injury. Panel on the left is an example of good quality T1 -weighted data. Panel on 
the right is an example of poor quality T1 -weighted data requiring re -acquisition in the 
same imaging session due to signs of motion artifact (e.g. ringing).  
 
6.4.4 Freesurfer Analyses of Cortical and Subcortical  Volume  
 
For each participant, the 3D isotropic MP RAGE data is processed via the Freesurfer 
v5.0.0 ( www.surfer.nmr.mgh.harvard.edu ) image processing stream (recon -all –all). 
Each brain is skull -stripped and segmented into 3 classes of voxels: gray matter, white 
matter, and cerebrospinal fluid (Dale & Sere no, 1993; Dale et al., 1999). Subsequently, 
the cortex is parcellated for individual gyri yielding morphometric measures of volume 
within each gyrus (Fischl & Dale, 2000). Once data sets have completed the Freesurfer 
pipeline, the color -coded segmentation maps are visually reviewed using 
Freesurfer’sTkmedit viewer (Figure 6a). Inaccurate boundary delineations of non - 
cortical structures and white matter are manually edited and the data re -processed via 
the second and third stages of the Freesurfer pipeline.  Color -coded cortical parcellation 
maps (Figures 6b and 6c) will also be reviewed via Freesurfer’s Tksurfer viewer for any 
inaccuracies that require editing. Quantitative non -cortical volumes are extracted from 
the aseg.stats file; surface -based cortical d ata (e.g. volume) are extracted from the  
?h.aparc.annot files.  
 
Figure 6.  
A B C 

ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 26 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Figures 6 A/B/C: Example segmentation of subcortical structures and parcellation of 
cortical gyri based on delimiting sulci. Panel on the level demonstrates vo lume -based 
subcortical segmentation of subcortical GM structures. Panels on the right demonstrate 
surface -based color -coded parcellation of cortical gyri from lateral and medial views of 
the left hemisphere.  
 
6.4.5 DTI Processing and  Analysis  
 
DTI data will be r eviewed for image quality during acquisition and re -acquired in the 
same imaging session based on real -time evaluation of imaging data and decisions 
made by Dr. Juranek. The isotropic 32 -direction DTI dataset will be processed and 
analyzed using FSL v4.1.7  (FMRIB’s Software Library, www.fmrib/ox.ac.uk/fsl). Minor 
head motion and eddy currents will be corrected with the Eddy Current Correction tool 
in FSL’s Diffusion Toolbox v2.0. FSL’s FUGUE module will be used to unwarp 
geometric distortions in the EPI -based DTI dataset with the gradient echo field map, 
correcting for EPI -related distortions in the DTI dataset (particularly fronto -orbital 
susceptibility regions) to improve co -registration with T1 structural images. Skull - 
stripping and removal of non -brain tissue is performed using BET v2.1. Diffusion 
tensors are reconstructed using FSL’s DTIFIT tool within the Diffusion Toolbox.  
 
6.4.6 DTI Co -Registration with Same Subject’s  aMRI  
 
FMRIB’s Linear Image Registration Tool v5.5 (FLIRT) is used to perform co -registration 
between each subject’s T1 -weighted series and corresponding non -diffusion -weighted 
series from the DTI dataset. The resultant transformation matrix, and the calculation of 
its inverse, provides the basis for co -registering the tractography results (performed in 
diffusion space) and volumetric results (performed in T1 space). For group -level 
analyses, a study -specific template will be constructed within FSL by pooling and 
aligning the FA maps of all study participants using a non -linear registration algorithm 
included with FSL (FNIRT).  Although FSL includes FA templates, these were 
generated from adult subjects and may introduce some error in our analyses of pediatric 
data. 
 
6.4.7 Region of Interest and Fiber Tracking Analyses for DTI  Data  
 
Using FSL’s ProbtrackX tool, probabilistic tractography methods are used for fiber 
tracking of major WM bundles. Combined use of color -coded tensor maps (Douek, 
Turner et al. 1991) generated b y FSL’s DTIFIT tool co -registered with the high 
resolution anatomy available in the T1 -weighted series will facilitate tractography by 
utilizing the seed -to-mask feature in ProbtrackX where one mask is used as the seed 
mask and one or more masks are used a s waypoints/targets. Such “masked -based” 
tractography reliably generates well -characterized tracts across study participants while 
preserving individual topology. In the ROI -based analyses FA values will be computed 
for major white matter bundles including  three branches of the superior longitudinal 
fasciculus (SLF I, SLF II, SLF III) from the arcuate fasciculus [AF]), the corticospinal 
tract (CST), and the corpus callosum (CC). Using methods of tract delineations 
described by Catani (2008), Makris (2005), and Glasser (2008), Figures 7 A/B illustrates 
the AF with 3 branches of the  SLF.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 27 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Figure 7  
A B 
Figures 7 A/B: Integration of multi -modal imaging data. Cortical GM masks are 
displayed in a 3D viewer with results of mask -based tractography of the 
arcuatefasiculus. Separate branches of the SLF (e.g. I,II,III) are evident in distinct 
terminations in superior frontal (SLF I), middlefrontal (SLF II), and inferior frontal (SLF  
III) cortices. Panel on the right represents the same data with the corti cal GM more 
transparent(s) to view the underlying tractography results. AF: lateral to cingulum 
bundle connecting posterior temporal (dark blue=bank of the superior temporal sulcus) 
with parietal (green=supramarginal) and frontal cortices; SLF I: branches into superior 
frontal (light blue); SLF II: branches into middle frontal (tan); SLF III: branches into 
inferior frontal (yellow).  
 
For analysis of inter -hemispheric connectivity by the corpus callosum, Freesurfer - 
generated volumes as well as DTI measures of FA and MD from five subdivisions of the 
corpus callosum (e.g. anterior=pink, mid -anterior=green, central=yellow, mid - 
posterior=blue, and posterior=red) will be related to neurobehavioral assessments of 
function and outcome.  
 
Figure 8 
A 
 
 
For investigating motor networks , Freesurfer -generated volumes of midbrain 
subcortical regions (e.g., thalamus and basal ganglia) will be related to measures of 
motor performance and processing speed.  
Figure 8, A/B: 
Examples of corpus 
callosum tractography 
results from each 
subdivision overlaid 
onto the same subject’s 
T1-weighted  volume.  
B Figures 8  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 28 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   
Figure 9   
Figure 9: Reconstruction of right cst using FSL’s prob - 
abilisti ctractography methodology (red/yellow 
probability map) overlaid onto color -coded 
reconstruction of diffusion tensors 
(red=interhemispheric; blue=superior -inferior; 
green=anterior -posterior).  
 
 
 
 
Additionally, Freesurfer -generated volumetric measures from primary motor cortex and 
DTI measures of FA and MD from the corticospinal tract (CST) will be related to 
neurobehavioral assessments of function and outcome.  
 
To study language networks, Freesurfer -generated volumetric measures from inferior 
frontal regions (e.g. pars opercularis and pars triangularis in yellow), temporal regions 
(superior - and middle -temporal not shown), and parietal regions (e.g. supramarginal 
and angular in green) will be related to language measures. Furtherm ore, DTI 
measures of FA and MD from the same GM regions and the AF/SL (in red) will be 
related to neurobehavioral assessments of function and outcome (Figure 10).  
 
Figure 10  
 
 
 
 
 
 
 
 
6.4.8 MRI Quality Control  Procedures  
 
At the time of acquisition, we have proce dures to check the aMRI and DTI data for 
outliers and confounding artifacts due to acquisition (e.g. image geometric distortions, 
field in homogeneity, signal -to-noise -ratio) and motion. If problems occur during scan 
acquisition, the sequence will be repea ted to optimize image quality within the same 
imaging session based on real -time evaluation of imaging data and decisions made by 
Dr. Juranek. All post -processing procedures of aMRI and DTI data include highly 
interactive protocols (i.e., not fully automat ed) requiring visual inspection of the data at 
each processing stage, which provides the best assurance of image quality. A standard 
water phantom will document and monitor scan quality at each imaging session. Post - 
processing procedures include quantitat ive evaluation of eddy currents and head 
movement using ExploreDTI v4.8.1 software provided by Dr. Leemans. Evaluation of 
DTI data acquired from our living phantom in Houston is presented below in Figures 11 
and 12.  Our criteria for disqualifying DTI data sets and re -acquiring DTI data within the  

ACT for CP Protocol V18  
Document Version Date: 18 OCT 2 017 Page 29 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   same imaging session are translations greater than one voxel (e.g. 2 mm) or rotations 
greater than 1˚.  
 
Figure 11  
Figures 11: Quantitative evaluation of DTI data quality using Explore DTI v 4.8.1. O n the 
left, the percentage of outlier voxels is plotted as a function of diffusion -weighted 
gradient direction number and slice number. On the right, rotations, translations, scale, 
and skew are plotted for each cardinal plane as a function of diffusion -weighted 
direction  number.  
 
6.4.9 Secondary Imaging Outcome Measures & Correlation with Functional  Outcome  
 
As noted in the section, “CP Neuroimaging”, cerebral palsy is a clinical diagnosis 
comprising a heterogeneous group of patients.  This heterogeneity is manifest both in 
the dominant clinical symptom complex, but also in the imaging correlates of the 
symptoms.  To that end, prior to treatment this study will quantify the degree of 
functional impairment (GFCMS level), and correlate it with the CP subtype an d imaging 
abnormality. The imaging ROIs will be prospectively identified pre -treatment. Then, 
according to the qualitative and quantitative metrics, the imaging data will be recorded. 
Post-treatment, these same ROIs will be compared to the baseline data, a nd correlated 
with any changes in functional outcomes as measured by specific tasks on the GFCMS. 
Ultimately, the changes in WM and GM ROIs that are associated with CP will be 
compared with and without treatment using autologous bone marrow derived 
mononuc lear cells or autologous cord blood mononuclear cells. These data will provide 
a structural metric around which future studies could be powered. Further, these data 
may provide potential mechanistic targets in terms of structural preservation and 
restorati on in patients with CP.  
 
7. MANAGEMENT OF ADVERSE  EXPERIENCES  
 
There are currently no neuroprotective/restorative treatments for CP in adults or 
children. Any potential risks must be weighed against the lack of treatment alternatives.  

ACT for CP Protocol V18  
Document Version Date: 18 OC T 2017  Page 30 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   The majority of the risk related to the study is associated with the bone marrow harvest 
and infusion periods and are discussed in section 6.2.  
 
7.1 Infection  
 
There have been studies on complications of marrow harvest, and these studies note a 
0.1-0.4% seriou s complication rate including: cellulitis at aspiration site, pneumonia and 
bacterial sepsis (Cairo, 1989; Jin, 1985; Kessinger, 1987). It is anticipated that the 
infectious risk will be lower than that reported in the oncology/BMT literature due to the 
relative immunocompetence of the CP population. We had no infections in our Phase I 
Trial. Parent(s)/LAR will receive detailed instructions at discharge regarding monitoring 
for signs of infection. There will be daily contact with the parent(s)/LAR for the f irst 21 
days post -infusion for safety monitoring.  
 
7.2 Other Harvest Related  Issues  
 
Bone marrow aspiration may cause discomfort. Hemorrhage, nerve injury and bone 
fracture are rare but reported complications that will monitored.  Because the 
autologous BMMNCs  used, are intravenously infused we do not anticipate any adverse 
reaction to them as may be occur in allogenic bone marrow transplants. Because this 
type of treatment has only been reported in head injured children in our Phase I trial, we 
may encounter o ther unexpected and unforeseen complications related to this 
treatment.  
 
7.3 Psychological and Functional Outcome  Testing  
 
Subjects enrolled in the trial will be asked to take tests of memory, attention and motor 
skills. Parent(s)/LAR will be asked to fill out  questionnaires that ask about the child’s 
learning and behavior. Measures will be taken to minimize any stress participants may 
experience with testing procedures. All tests will be conducted in a private room located 
in the Outpatient Pediatric Surgery C linic. Ample time will be given for completion of the 
tests.  
 
7.4 Loss of  Confidentiality  
 
There is a potential risk of loss of confidentiality of subject information and data. All 
study related records will be stored in locked office and cabinets within the D ept. of 
Pediatric Surgery.  Access to study records will be restricted to research team 
members, the study monitor, and UT IRB representatives.  Case report forms will 
contain only the subject’s study ID. The study database will reside within UTHealth 
Medi cal School, firewall protected, zone 100 servers. Assess to the study database will 
be limited to research team members.  
 
8. CRITERIA FOR INTERVENTION  DISCONTINUATION  
 
8.1 Description of Subject  Completion  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 31 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Subjects are considered to have completed the study if they have undergone the 
BMMNC/hUCB infusion at either the baseline or the 1 year cross -over visit and have 
completed the 2 year end of study visit.  
 
8.2 Withdrawal of Individual  Subjects  
 
The Principal Investigator will make every reasonable effort to keep each subject in the 
study through the 2 year visit. If a subject withdraws from the study, the reason for  
withdrawal must be documented in the study chart. Possible reasons for withdrawal 
include: adverse experiences, protocol deviation, including non -compliance, lost to 
follow -up, discretion of investigator or DSMB, or other regulatory agency/body.  
Subjects will be withdrawn from the study immediately if any of the following occur:  
a. The subject or their parent(s)/LAR requests withdrawal from the  study.  
b. The investigator believes it is in the best interest of the  subject.  
c. There is clinically significant deterior ation of the subject’s medical status  that 
warrants termination from the  study.  
d. There are clinically significant abnormal laboratory results that  warrant 
termination from the  study.  
 
8.3 Withdrawal of Subject from the Study Following Adverse  Events  
 
The investigator must apply his clinical judgment to determine if an adverse event (AE) 
is of sufficient severity to require that the subject should immediately be withdrawn from 
the study. If the withdrawal from the study is due to an AE, the subject should b e given 
appropriate care under medical supervision until the symptoms of the AE resolve or 
his/her condition becomes stable. Subsequent review by the MSM, DSMB, or IRB may 
also result in the suspension of further trial enrollment (see Stopping Rules).  
A subject (or Parent/LAR) may also voluntarily withdrawal from treatment due to what 
he/she perceives as an intolerable AE, or for any other reason. If voluntary withdraw is 
requested, or if withdrawal occurs for any reason, the subject should be asked to 
continue (at least limited) scheduled evaluations, complete an end -of-study evaluation, 
and be given appropriate care under medical supervision until the symptoms of any AE 
resolve or the subject’s condition becomes stable.  
 
8.4 Procedures for Handling  Withdrawals  
 
In case of early withdrawal, subjects will be asked to continue (at least limited) 
scheduled evaluations and to complete an end -of-study evaluation which includes all 
scheduled exams, procedures, and laboratory tests as if it is the 12 Month visit; and 
should be given appropriate care under medical supervision until the symptoms of any 
AE resolve or the subject’s condition becomes stable. If the subject is unwilling or 
unable to complete visits, he/she will be asked to return for the end -of-study visit an d 
then should be followed through telephone calls by the coordinator. Subjects who do 
not complete study treatment or all follow -up will be asked to provide the same data as 
subjects who withdraw.  
 
8.5 Subject  Replacement  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 32 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Subjects will not be replaced once randomized.  
 
9. STATISTICAL  CONSIDERATIONS  
 
9.1 Outcomes  
 
9.1.1 Primary Safety  Objective  
 
Baseline characteristics of participants will be summarized using descriptive statistics 
and tabulations. Evaluation of data will be guided by exploratory analyses. All results 
will be reported as point estimates (percentages for binary outcomes and means  SD 
and median (range) for continuous outcomes) with corresponding interval estimates 
(two-sided 95% confidence intervals). No adjustments for multiple comparisons will be 
made and a p -value of 0.05 will be considered statistically significant.  
 
These dat a are collected over time and will be longitudinal in nature with several pre - 
defined points of follow -up. We will use analytic strategies and methods applicable to 
such desigrns.  For each participant in the cohort we have a set of “k” independent  
variab les x  (x1 , x2 ,..., xk ), of which some may be time varying (e.g., blood pressure) and  
others do not change over time (e.g., gender). In addition, the outcome variables of 
interest are also measured repeatedly over time (e.g., temperature, signs of infe ction, 
neurological exams, CBC, chem -20). We plan to explore any changes over time 
between hospital discharge and long -term follow -up at 6 months, 1 year, and 2 years 
after cell treatment with repeated measure model analyses. In this study, we plan to 
explore and identify potential factors associated with time to SAEs, AEs, death (refer to 
section 6.2) , loss to follow -up (short term and long term), and improvements in 
functional outcomes (refer to section 6.3) .  We plan to explore the factors associated 
with the time to an event using survival analysis methods which incorporate information 
about the timing of withdrawals, deaths, and functional improvements (if any) of 
subjects during the follow up period. We plan to first use descriptive statistics to explo re 
the characteristics of the subjects among events and then will use the Kaplan -Meier 
method to estimate the time to an event. Combined, these secondary analyses may 
provide useful preliminary estimates for the design of future cell  studies.  
 
9.1.2 Secondary  Objectives/Outcomes  
 
The models proposed will be tested using general linear models (GLM). We will 
examine all variables to determine that they are relatively symmetric and unimodal, 
examine group variances for obvious deviations, and examine the residuals  from each 
model to ensure reasonable adherence to the assumptions of normality and 
independence. If any variables violate the assumptions, we might transform skewed 
variables. We will evaluate the comparability of our groups on key demographic 
variables a nd will covary variables if necessary (e.g., socioeconomic status).  
For Efficacy Outcome Measure 1 (refer to section 1.2.1) , we will use repeated measures 
ANOVA or ANCOVA (including intracranial volume as a covariate for macrostructure 
analyses) with Group  (Treatment, Control) as the between -subjects factor and Time of 
Assessment (baseline, 1 year, and 2 years) and Age as the within -subjects factors. We  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 33 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   will examine the Age x Group x Time interaction and two -way interactions for each 
analysis and will trim non -significant terms from each model. If GM and WM volumes or 
DTI metrics vary across time, we will complete trend analysis to identify whether a linear 
or quadratic function best fits the data. Dependent variables will be evaluated in 
separ ate analyses. Dependent variables will be 1) the volume of whole brain gray 
matter, white matter, and CSF; 2) FA of core white matter pathways (corpus callosum, 
arcuate/superior longitudinal fasciculus), and 3) MD of gray matter in frontal and 
temporal cor tical regions.  
 
To examine brain -behavior relations (Efficacy Outcome Measure 2, section 1.2.2) , we 
will first examine the distribution of variables to determine whether assumptions are met 
for Pearson or Spearman correlation approaches. To evaluate streng th of brain - 
behavior relations, outcome scores will be correlated with specific macrostructural and 
microstructural metrics from the DTI. For global outcome, the GOS -EC score will be 
correlated with gray and white matter volumes and corpus callosum FA. Fo r 
neurocognitive outcomes, the accompanying table shows the expected relations 
between outcomes and gray and white matter microstructural metrics. We expect 
positive correlation of dependent variables with FA and negative correlation of 
dependent variables  with MD. Similar to our recent approach (Juranek et al., 2012), 
brain -behavior analysis will also be completed using individual outcomes as dependent 
variables with group (Treatment, Control) and MRI/DTI variables as independent 
variables (e.g., examine t he effect of group and FA of the corticospinal tract on fine 
motor scores; examine group and MD of dorsolateral frontal cortex on working memory 
scores).  
 
Expected Relations of Neurocognitive Outcomes with Gray and White Matter 
Microstructure from Diffusio n Tensor Imaging.  
Neurocognitive 
Outcome  Microstructure: 
Gray Matter MD  Microstructure: 
White Matter FA  
IQ  Corpus callosum  
Motor  
GMFM -88  Corticospinal  
Verbal Fluency 
PPVT4/EVT2   Arcuate/superior longitudinal 
fasciculus  
Learning/Memory 
NEPSY -II Temporal cortex, 
hippocampus   
 
9.2 Sample Size and  Accrual  
 
As this is primarily a safety study, we should be able to ascertain serious AEs with 
15patients/group. We have already identified approximately 15 patients who meet 
screening criteria for enrollment,  thus accrual should not be problematic.  
 
10. DATA COLLECTION, SAFETY MONITORING, ADVERSE EVENTS  REPORTING  
 
10.1 Records  Retention  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 34 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   The period of paper and electronic record retention will be consistent with the record 
retention policies of the Univers ity of Texas Health Science at Houston and the 
applicable regulatory agencies for the trial, including the FDA and OHRP. However, in 
certain instances, documents should be retained for a longer period if required by the 
applicable regulatory agency.  
 
10.2 Quality  Assurance  
 
The study will be conducted according to Good Clinical Practice (GCP) guidelines, the 
Declaration of Helsinki, US 21 Code of Federal Regulations (CFR) Part 50 – Protection 
of Human Subjects, and Part 56 – Institutional Review Boards.  
 
All pediatric research at the University of Texas Health Science Center at Houston is 
subject to random audits throughout the year by a monitor from the institution’s IRB as 
well. 
 
10.3 Independent Medical Monitor  (IMM)  
 
A monitor from Juno Research Inc. will serve as the IMM. Juno Research has provided 
this service for previous TBI trials at UT Health and Children’s Memorial Hermann 
Hospital.  The IMM will provide oversight of the protocol and ongoing study activities 
with an emphasis on data integrity and qua lity assurance, protocol adherence, study 
participant safety issues, and in particular the review of AEs and SAEs. In addition to 
data quality, the IMM will review consent forms and regulatory documents as part of the 
monitoring plan.  
 
The IMM will make re commendations to the PI regarding continuation, modification or 
conclusion of the trial, while protecting the confidentiality of the trial data. In the unlikely 
event of unexpected or unduly high rate of SAEs, the IMM will notify the MSM, the 
DSMB, and the  PI of these findings. The IMM will review the medical record and data 
collected following post -infusion Day 21 of the first subject. Thereafter, they will review 
after subject 5, and each subsequent fifth subject, unless another visit is recommended 
by th e MSM, DSMB, FDA or IRB.  
 
10.4 Medical Safety Monitor  (MSM)  
 
George Carrum, MD will serve as the MSM. Dr. Carrum is faculty for the Department of 
Hematology/Oncology -Bone Marrow Transplantation at The Methodist Hospital and the 
Center for Cell and Gene Therapy in Houston, Texas. Dr. Carrum is experienced in the 
field of cellular therapies, including bone marrow harvest and transplantation. In 
addition, he is experienced in the release criteria of cellular products and potential AEs 
related to infusion toxicity. He has served on previous DSMBs, including having served 
as the DSMB Chair of the Phase 1 Pediatric TBI stem cell trial. Dr. Carrum’s primary 
responsibility will be to review SAEs in real time to ensure good clinical practice and to 
quickly identify safety  concerns. He may suggest protocol modifications to prevent the 
occurrence of particular adverse events. He will remain blinded to the treatment 
assignment, unless the DSMB approves unblinding, and will review SAE reports 
following post -infusion Day 21 of each subject (if applicable) for submission to the PI,  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 35 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   DSMB, FDA and IRB, and prior to each DSMB meeting. Dr. Carrum is not affiliated with 
UT Health in any manner, nor does he practice within the Memorial Hermann Hospital 
System. The MSM wil l work in conjunction with the IMM and the DSMB to ensure the 
safety of the intervention in this trial.  
 
All reports of hospitalization due to infection or neurological events, and all subject 
deaths will be reported to the MSM.  
 
10.5 Data Safety and Monitoring  Board  (DSMB)  
 
Although this is a single site, relatively small sample size study, we plan to use a DSMB 
instead of a SMC -monitored approach. DSMB membership, responsibilities, meetings, 
and DSMB reports are described in the DSMB Charter (Appendix C).  
 
10.6 Adverse Experience  Reporting  
 
10.6.1  Overview  
 
All safety data will be reviewed by the Medical Safety Monitor (MSM) in real time, as 
well as, the Independent Medical Monitor (IMM) at regular monitoring visits according to 
the monitoring plan.  Based on the data, the  MSM may suggest protocol modifications 
to prevent the occurrence of particular adverse events.  The data will also be reviewed 
by the DSMB at bi -annual meetings, or on an as -needed basis if required. The DSMB 
can recommend protocol modifications and/or st udy termination because of safety 
findings. All FDA, OHRP and the University of Texas Health Science Center at Houston 
IRB requirements for reporting adverse experiences will be  followed.  
 
10.6.2  Definitions  [21CFR310.305]  
 
10.6.2.1  Adverse  Experience  
 
Any adverse event a ssociated with the use of a drug or biologic in humans, whether or 
not considered drug related. For this protocol, temporally association with the use of 
the cellular product will be considered.  
 
10.6.2.2  Disability  
 
A substantial disruption of a person's ability t o conduct normal life functions.  
 
10.6.2.3  Life-Threatening Adverse  Experience  
 
Any adverse experience that places the patient, in the view of the initial reporter, at 
immediate risk of death from the adverse experience as it occurred, i.e., it does not 
include an adverse experience that, had it occurred in a more severe form, might have 
caused death.  
 
10.6.2.4  Serious Adverse  Experience  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 36 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Any adverse experience that results in any of the following outcomes: Death, a life - 
threatening adverse experience, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant disability/incapacity, or a congenital 
anomaly/birth defect. Important medical events that may not result in death, be life - 
threatening, or require hospital ization may be considered a serious adverse drug 
experience when, based upon appropriate medical judgment, they may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  
 
10.6.2.5  Unexpected Adverse  Experience  
 
Any adverse experience not listed in the current labeling for the drug or biologic product. 
This includes events that may be symptomatically and pathophysiologically related to an 
event listed in the labeling, but differ fr om the event because of greater severity or 
specificity. “Unexpected," as used in this definition, refers to an adverse experience that 
has not been previously observed.  
 
10.7 Recording Adverse  Experiences  
 
Safety data will be recorded on CRFs designed for this  purpose. Adverse experiences 
will be collected from the time of randomization until completion of study visits or until 30 
days after premature withdraw from the study. If an abnormal value or result is 
determined by the investigator to be clinically sign ificant and/or temporally related, the 
adverse experience will be recorded on the appropriate CRF.  
 
10.7.1  Grading  Criteria  
 
The severity of adverse events experienced by the subjects will be graded according to 
the criteria set forth in the National Cancer Insti tute’s Common Toxicity Criteria for 
Adverse Events Version 4.0. This document (CTCAE v4.0) provides a common 
language to describe levels of severity, to analyze and interpret data, and to articulate 
the clinical significance of all adverse events.  
Adverse events will be graded on a scale from 1 to 5 according to the following 
standards in the NCI -CTCAE:  
Grade 1 = mild adverse event 
Grade 2 = moderate adverse event  
Grade 3 = severe and undesirable adverse event 
Grade 4 = life -threatening or disabling adverse  event 
Grade 5 = death  
 
10.7.2  Attribution  Definitions  
 
The relation, or attribution, of an adverse event or experience to the investigation 
product will be determined by the principal investigator and will be recorded on the CRF. 
The relation of an adverse event  to the treatment will be determined according the 
definitions in the NCI -CTCAE.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 37 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   10.8 Termination of the Cellular Product  Infusion  
 
If at any point during the cellular product infusion (BMMNCs or hUCB) the subject 
experiences symptoms associated w ith anaphylaxis (such as wheezing, blood pressure 
changes, rash, vomiting), the infusion will be stopped. The subject will continue to be 
enrolled and followed in the study through 2 years.  
 
10.8.1  Stopping  Rules  
 
1. ANY death that is deemed by the DSMB to be related or possibly related to the 
study  treatment.  
2. Both P:F ratio < 70 AND PaC02 > 90 within the first 48 hours post BM  infusion 
occurring in a single  subject.  
3. AST/ALT > 900 U/dl in the first 24 hours post infusion occurring in a single 
subject.  
4. Grade 4 – 5 CNS cerebrovascular ischemia event or Grade 4 – 5 seizure event 
as defined in the NCI CTCAE v4.0 occurring within 12 hours of BMMNCs or Cord 
blood Cell  re-infusion.  
5. Any Grade 4 – 5 Adverse Event as defined in the NCI CTCAE v4.0 and 
determined to be temp orally -related by the Medical Safety Monitor and/or  DSMB.  
 
10.9 Communication and Reporting Serious Adverse Events  (SAEs)  
 
Any grade 4 – 5 adverse event (CTCAE v4.0) deemed by the MSM and/or the DSMB to 
be temporally associated with the treatment will prompt ce ssation and trigger the 
stopping rules.  Triggering the stopping rules will prompt notification of the FDA and 
IRB. If a patient that receives study treatment dies, and the DSMB determines that it 
may be related to the treatment, then the study will be ter minated and a comprehensive 
safety review undertaken.  
 
10.9.1  Timeline for Reporting  SAE’s  
 
1. The PI will notify the MSM and DSMB of any communication from the  FDA 
concerning the trial within 72 hours of  notification.  
2. MSM and DSMB written reports regarding SAEs wil l be submitted to the  IRB 
within five working  days.  
3. Subject deaths will be reported to the MSM and IRB by telephone within 24 
hours  of discovery,  and entered  into IRB electronic  database  (iRIS)  within  five 
working  days.  
4. SAE’s directly related to the cellular infusion will be reported to the MSM and 
IRB within five days of discovery and entered into the IRB electronic database 
(iRIS).  
5. Other AEs do not need to be reported if the PI determines the AE is expected 
or due to the natural  progression  of the subject’s  underlying  disease,  however 
an internal log/record will be kept of these for tracking potential risks and 
reporting  purposes.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 38 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   11. HUMAN  SUBJECTS  
 
11.1 Institutional Review Board (IRB) Review and Informed  Consent  
 
This protocol and the inform ed consent document and any subsequent modifications 
will be reviewed and approved by the University of Texas Health Science Center at 
Houston Committee for the Protection of Human Subjects (CPHS), also known as the 
IRB. A signed consent form will be obtai ned from the parent(s) or Legally Authorized 
Representative (LAR) after a thorough explanation of the purpose of the study, the 
study procedures (including the bone marrow harvest/sham procedure, infusion, MRI, 
and assessment procedures), follow -up visits,  potential risks/benefits, the time 
commitment involved, and measures to protect confidentiality. Adequate time will be 
given for questions. A copy of the signed consent form will be given to the 
parent(s)/LAR. In addition, a written note will be placed in  the patient’s medical chart 
documenting the communication between investigator and the parent(s)/LAR about the 
research.  
 
11.2 Subject  Confidentiality  
 
To protect against loss of confidentiality, subjects’ names will be replaced by a study 
identification number on case report forms, reports and on computer entry into the 
database. No identifying information will be mentioned in any presentations or 
publications. Strict security will be maintained, with limited access only to the password 
protected database , and all personnel involved will be trained to be aware of the 
importance of maintaining privacy. Clinical information will not be released without 
written permission of the subject (or parent(s)/LAR), except as necessary for monitoring 
by the DSMB, IRB, FDA, or other State or Federal regulatory agencies.  
 
11.3 Study  Modification/Discontinuation  
 
The study may be modified or discontinued at any time by the DSMB, IRB, the OHRP, 
the FDA, or other government agencies as part of their duties to ensure that research  
subjects are protected.  
 
12. PUBLICATION OF RESEARCH  FINDINGS  
 
Publication of the results of this trial will be governed by the policies and procedures 
developed by the Executive Committee. Any presentation, abstract or manuscript will 
make available for review by the sponsor prior to submission.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 39 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   13. REFERENCES  
 
Cairo MS, VandeVen C, Toy C, Sender L. Clinical and laboratory experience in marrow 
harvesting in children for autologous bone marrow transplantation. Bone Marrow 
Transplant 4: 305 -308, 1 989. 
 
Catani M, Thiebaut de Schotten M. A diffusion tensor imaging tractography atlas for 
virtual in vivo dissections. Cortex. 2008 Sep;44(8):1105 -32. 
 
Cox CS Jr, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, Ewing -Cobbs 
L, Hasan KM, Day MC, Le e D, Jimenez F, Gee A. Autologous bone marrow 
mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery.  
2011 Mar;68(3):588 -600. 
 
Dale AM, Fischl B,Sereno MK. Cortical surface -based analysis I: Segmentation and 
surface reconstruc tion. Neuroimage 9: 195 -207, 1999.  
 
Dale A, Sereno MI. Improved Localization of cortical activity by combining EEG and 
MEG with MRI cortical surface reconstruction: A linear approach. Journal of Cognitive 
Neuroscience. 1993;5:162 -76. 
 
de Vasconcelos Dos Sa ntos A, da Costa Reis J, Diaz Paredes B, Moraes L, Jasmin, 
Giraldi -Guimarães A, Mendez -Otero R. Therapeutic window for treatment of cortical 
ischemia with bone marrow -derived cells in rats. Brain Res. 2010 Jan 8;1306:149 -58. 
Epub 2009 Sep 30.  
 
Douek P, Tur ner R, Pekar J, Patronas N, Le Bihan D. MR color mapping of myelin fiber 
orientation. J Comput Assist Tomogr. 1991 Nov -Dec;15(6):923 -9. 
 
Fischl B and Dale AM. Measuring the thickness of the human cerebral cortex from 
magnetic resonance images. Proc Natl Acad Sci USA 97: 11050 -11055, 2000.  
 
Glasser MF, Rilling JK. DTI tractography of the human brain's language pathways. 
Cereb Cortex. 2008 Nov;18(11):2471 -82. 
 
Harris DT. Collection, processing and banking of umbilical cord blood for clinical use. 
Journal of  the Bellevue Obstetrical and Gynecological Society 2002;18:13 -21. 
 
Harris D. Collection, processing, and banking of umbilical cord blood stem cells for 
clinical use in transplantation and regenerative medicine. Lab Medicine 
2008;39(3):173 -178. 
 
Hoon AH Jr . Neuroimaging in cerebral palsy: Patterns of brain dysgenesis and injury. J 
Child Neurol. 2005 Dec;20(12):936 -9. 
 
Hoon Jr. A.H., Stashinko E.E., Nagae L.M., Lin D.D., Keller J., Bastian A., Campbell 
M.L., Levey E., Mori S., Johnston M.V., 2009. Sensory an d motor deficits in children  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 40 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   with cerebral palsy born preterm correlate with diffusion tensor imaging abnormalities in 
thalamocortical pathways. Dev. Med. Child Neurol. 51 (9), 697 –704. 
 
Jin NR, Hill RS, Petersen FB, Buckner CD, Stewart PS, A mos D, Appelbaum FR, Clift 
RA, Bensinger WI, Sanders JE, et al. Marrow harvesting for autologous marrow 
transplantation. Exp Hematol. 1985 Oct;13(9):879 -84. 
 
Kessinger A, Armitage JO. Harvesting marrow for autologous transplantation from 
patients with mali gnancies. Bone Marrow Transplant. 1987 Jun;2(1):15 -8. 
 
Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kobayashi T, Sato A, Kato S, 
Kasahara S, Ebihara Y, Nagamura -Inoue T, Tsuji K, Tojo A, Asano S. Cardiovascular 
toxicity of cryopreserved cord blood cell infusion. Bone Marrow Transplant 2008; 
41:861 -865. 
 
Kraus MF, Susmaras T, Caughlin BP, Walker CJ, Sweeney JA, Little DM. White matter 
integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging study. 
Brain. 2007 Oct;130(Pt 1 0):2508 -19. Epub 2007 Sep 14.  
 
Kumar R, Husain M, Gupta RK, Hasan KM, Haris M, Agarwal AK, Pandey CM, 
Narayana PA. Serial changes in the white matter diffusion tensor imaging metrics in 
moderate traumatic brain injury and correlation with neuro -cognitive f unction. J 
Neurotrauma. 2009 Apr;26(4):481 -95. 
 
Lu D, Mahmood A, Wang L, Li Y, Lu M, Chopp M. Adult bone marrow stromal cells 
administered intravenously to rats after traumatic brain injury migrate into brain and 
improve neurological outcome. Neuroreport 1 2: 559 -563, 2001.  
 
Makris N, Schlerf JE, Hodge SM, Haselgrove C, Albaugh MD, Seidman LJ, Rauch SL, 
Harris G, Biederman J, Caviness VS Jr, Kennedy DN, Schmahmann JD. MRI -based 
surface -assisted parcellation of human cerebellar cortex: an anatomically specifi ed 
method with estimate of reliability. Neuroimage. 2005 May 1;25(4):1146 -60. 
 
Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth -Haerer A, Gantert M, Dinse HR, 
Dermietzel R, Jensen A. Spastic paresis after perinatal brain damage in rats is reduced 
by human cord blood mononuclear cells. Pediatr Res. 2006 Feb;59(2):244 -9. 
 
Panigrahy A., Barnes P.D., Robertson R.L., Sleeper L.A., Sayre J.W., 2005. 
Quantitative analysis of the corpus callosumin childrenwith cerebral palsy and 
developmental delay: correlatio n with cerebral white matter volume. Pediatr. Radiol. 35 
(12), 1199 –1207.  
 
Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, 
Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belém L, Vivacqua R, Rangel FO, 
Esporcatte R, Geng YJ, Vau ghn WK, Assad JA, Mesquita ET, Willerson JT. 
Transendocardial, autologous bone marrow cell transplantation for severe, chronic 
ischemic heart failure. Circulation. 2003 May 13;107(18):2294 -302. Epub 2003 Apr 21.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 41 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen 
KM, Gentleman S, Heckemann RA, Gunanayagam K, Gelosa G, Shar p DJ. 
Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 
2011 Sep;70(3):374 -83. doi: 10.1002/ana.22455. Epub 2011 Jun 27.  
 
Rosenthal J, Brown H, Harris D. Stem cell recovery following implementation of an 
automated cor d blood processing system in a high volume laboratory. Biol Blood 
Marrow Transplant 2008;14(2):S42.  
 
Smith DM, Weisenburger DD, Bierman P, Kessinger A, Vaughan WP, Armitage JO. 
Acute renal failure associated with autologous bone marrow transplantation. Bon e 
Marrow Transplant 1987; 23:195 -201. 
 
Son SM, Ahn YH, Sakong J, Moon HK, Ahn SH, Lee H, Yu IK, Shin YJ, Jang SH, 2007. 
Diffusion tensor imaging demonstrates focal lesions of the corticospinal tract in 
hemiparetic patients with cerebral palsy. Neurosci. Le tt. 420 (1), 34 –38. 
 
Son SM, Park SH, Moon HK, Lee E, Ahn SH, Cho YW, Byun WM, Jang SH, 2009. 
Diffusion tensor tractography can predict hemiparesis in infants with high risk factors. 
Neurosci. Lett. 451 (1), 94 –97. 
 
Sun J, Allison J, McLaughlin C, Sledge L , Waters -Pick B, Wease S, Kurtzberg J. 
Differences in quality between privately and publicly banked umbilical cord blood units: 
a pilot study of autologous cord blood infusion in children with acquired neurologic 
disorders.  Transfusion.  2010  Sep;50(9):1980 -7. doi: 10.1111/j.1537 -2995.2010.02720.x.  
 
Thomas B, Eyssen M, Peeters R, Molenaers G, Van Hecke P, De Cock P, Sunaert S. 
Quantitative diffusion tensor imaging in cerebral palsy due to periventricular white 
matter injury. Brain. 2005 Nov;128(Pt 11):2562 -77. Epub 2005 Jul 27.  
 
Towsley K, Shevell MI, Dagenais L; REPACQ Consortium. Population -based study of 
neuroimaging findings in children with cerebral palsy. Eur J Paediatr Neurol. 2011 
Jan;15(1):29 -35. 
 
Wilde EA, Hunter JV, Newsome MR, Scheibel RS, Bigler ED, Johnson JL, Fearing MA, 
Cleavinger HB, Li X, Swank PR, Pedroza C, Roberson GS, Bachevalier J, Levin HS. 
Frontal and temporal morphometric findings on MRI in children after moderate to severe 
traumatic brain injury.  J Neurotrauma. 2005 Mar;22(3):333 -44. 
 
Yoshida S, Hayakawa K, Yamamoto A, Okano S, Kanda T, Yamori Y, Yoshida N, Hirota  
H. Quantitative diffusion tensor tractography of the motor and sensory tract in children 
with cerebral palsy. Dev Med Child Neurol. 2010 Oct;52(10):935 -40. doi: 
10.1111/j.1 469-8749.2010.03669.x. Epub 2010 Apr 12.  
 
Yoshida S, Hayakawa K, Oishi K, Mori S, Kanda T, Yamori Y, Yoshida N, Hirota H, 
Iwami M, Okano S, Matsushita H. Athetotic and spastic cerebral palsy: anatomic 
characterization based on diffusion -tensor imaging. Rad iology. 2011 Aug;260(2):511 - 
20. Epub 2011 May 9.  
IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017  ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 42 of 49   14. APPENDIX  A 
Bone Marrow Group:  
 
 
* The 6 month  return  visit window  is +/- 14 days  from infusion  and +/- 21 days  for the 1 and 2 year return  visits.  
1   The informed consent document will be sent to the family/LAR during the screening period and reviewed by conference call befo re the baseline visit.  
2. Infectious Disease Tests include HIV, Hepatitis, Syphilis, and West Nile Virus.  
3   Lab tests include CBC with Differential and Platelets, and Comprehensive Metabolic/Coagulation Panels.  
4   Post-infusion CBC and basic chemistry pannel on day 21 (+/ - 7 day s). 
5   Subjects will receive 24 hours of monitoring post -infusion before discharge.  
6. Placebo Crossover to BMMNC harvest and stem cell infusion.  

IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017  ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 43 of 49   Cord Blood Group:  
 
* The 6 month  return  visit window  is +/- 14 days  from infusion  and +/- 21 days  for the 1 and 2 year return  visits.  
1 The informed  consent  document  will be sent to the family/LAR  during  the screening  period  and reviewed  by conference  call before  the baseline  visit. 
2 Subject will have HLA & basic infectious disease tests prior to baseline visit. Maternal infectious disease tests will also b e required if not avialable from  CBR.  
3 After  the signed  informed  consent  document  is received,  CBR  will be contacted  to release  cord blood  information  (HLA  Type,  Cell Count,  Contaminates).  
4 Cord  blood  subjects  will be randomized  after comfirmation  of viable  cord blood  stem  cells,  confirmation  of HLA match,  and neg. infectious  disease  test results.  
5 CBR will ship the frozen hUCB to the GSCL 7 to 14 days before the visit. Umbilical cord blood for subjects assigned to the pl acebo group 
will not be released from CBR until the 1 year cross -over visit. 
6 Lab tests  include  CBC  with differential  and platelets,  comprehensive  metabolic  and coagulation  panels,  and hepatic  function  tests.  
7 Post-infusion CBC and basic chemistry pannel on day 21 (+/ - 7 days).  
8 Cross -Over Group Stem Cell  infusion.  
9 Subjects  will receive  24 hours  of monitoring  post-infusion  before  discharge.  

  
15. Appendix B:  Table of Psychological and Functional Outcome  Tests  
Age Motor  Adaptive Behavior  Visual -Spatial Processing  Learning  Language  
2-2.5 GMFM -88 VABS2  -- -- -- 
2.6-3 GMFM -88 VABS2  -- -- PPVT4/EVT2  
3 GMFM -88 VABS2  -- NEPSY -II PPVT4/EVT2  
4 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
5 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
6 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
7 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
8 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
9 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
10 GMFM -88 VABS2  MVPT -3 NEPSY -II PPVT4/EVT2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACT for CP  Protocol  V18 Page 44  of 49 
Document Version Date: 18 OCT  2017  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017  

ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 45 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   16. Appendix C:  DSMB  CHARTER  
 
DATA AND SAFETY MONITORING BOARD CHARTER  
 
Protocol Title:  Autologous Cell Therapies for Cerebral Palsy -Chronic (ACT for CP)  
Principal 
Investigators:  Charles S. Cox, Jr., MD, Sean Savitz, MD  
Co-Investigator:  Fabio Triolo, PhD, Maria Matuszczak, MD, Jenifer Juranek, PhD, 
Allison Dempsey, PhD, Claudia Pedroza, PhD  
Study Staff:  Joiya Arrington, MSN, RN, Steven Kosmach, MSN, RN, CCRC  
Protocol Number:  HSC -MS-12-0876  
BB IND Number:  || 
Sponsor:  CBR, Inc., TIRR Foundation, Let’s Cure CP Foundation  
Document Version 
Date:  18 OCT 2017  
 
Purpose:  
The purpose of this charter is to define the responsibilities of this Data and Safety Monitoring 
Board (DSMB), its membership, and timing of meetings. It will also provide the procedures 
used to carry out these responsibilities.  
 
DSMB Responsibilities:  
The DSMB has the following responsibilities:  
 Review and sign this charter signifying understanding of  responsibilities;  
 Review the research protocol, informed consent documents and plans for data safety and 
monitoring;  
 Evaluate the progress of the trial, including periodic assessments of data quality and 
timeliness, participant recruitment , accrual and retention, participant risk versus  benefit, 
performance of the trial site, and other factors that can affect study  outcome;  
 Consider  factors  external  to the study  when  relevant  information  becomes  available,  such 
as scientific or therapeutic developments that may have an impact on the safety of the 
participants or the ethics of the  trial; 
 Make recommendations to the PI about continuation, termination, or other modifications  of 
the trial based  on the observed  beneficial  or adverse  effects  of the treatment  under  study;  
 If appropriate, conduct interim analysis of efficacy in accordance with stopping criteria 
which  are clearly  defined  in advance  of data analysis  and have  the approval  of the DSMB;  
 Ensure the confidentiality of the trial data and the  results of monitoring;  and, 
 Recommend solutions to address problems with study conduct, enrollment, and sample 
size and/or data  collection.  
 
Membership:  
The DSMB will consist of at least three four members. Three members will constitute a 
quorum. All memb ers must be completely independent of the trial and have no financial, 
scientific, or other conflict of interest with the trial. Collaborators or associates of Charles 
Cox, MD, and Sean Savitz, MD, are not eligible to serve on the DSMB. The DSMB includes  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 46 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   experts in or representatives of the fields of relevant clinical expertise, clinical trial 
methodology, and biostatistics.  
 
The Chair is responsible for overseeing the meetings, and developing the agenda in 
consultation with the Principal Investigator. The chair is the contact person for the DSMB. 
DSMB membership is for the duration of the  clinical trial. If any members leave during the 
course of the trial, the Principal Investigator will appoint their replacement.  
 
Names, Affiliations and Contact Information  
 
DSMB Chair:  George Carrum, MD  
Affiliation:  The Methodist Hospital, Dept. of Hematology/Oncology -Bone 
Marrow Transplantation  
Phone:  713.441.1450  
Mobile:  713.562.0307  
Email:  gcarrum@tmhs.org  
 
Voting Member:  Ian Butler, MD  
Affiliation:  UTHealth, Professor of Pediatric Neurology  
Phone:  713.500.7142  
Pager:  713.760.1072  
Email:  ian.j.bulter@uth.tmc.edu  
 
Voting Member:  Amir Khan, MD  
Affiliation:  Medical Director, Children’s Memorial Hermann Neonatal ICU  
Contact 
Information:  Heather Justice (Executive Assistant) 713.500.5733 / 
heather.r.justice@uth.tmc.edu  
Phone:  713.500.5733  
Email:  amir.m.khan@uth.tmc.edu  
 
DSMB  
Coordinator  Steven Kosmach, MSN, RN, CCRC  
Affiliation:  UTHealth, Medical School, Dept. of Pediatric Surgery, Children’s 
Program in Regenerative Medicine  
Phone:  713.500.7329  
Mobile:  713.505.6883  
e-mail:  steven.kosmach@uth.tmc.edu  
 
DSMB members will disclose any real or perceived conflict(s) of interest. The DSMB will then 
determine the appropriateness of the member continuing to serve on the Board.  
 
Operational Plan:  
This DSMB will abide by its charter. The charter may be amended by a quorum vote of the 
Board at a scheduled meeting. The proposed amendment must be provided to the 
membership a minimum of ten business days prior to the proposed decision date.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 47 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Estimated Time Commitment:  
DSMB mem bers acknowledge the estimated time commitment serving on the DSMB as listed 
below. The estimate of time may be greater or less, depending on enrollment numbers and 
adverse events reported.  
 Treatment summary reviews may take approximately 30  minutes.  
 Two o r three subjects are projected to enroll each month and then enter the long -term 
follow -up phase of the study. Pending barriers to recruitment, it is anticipated that all 
baseline visits the 30 subjects will be completed by the end of  2014.  
 The DSMB will meet every 6 months or as needed. The estimated duration of each 
meeting is 1  hour.  
 
Protocol Information:  
DSMB members will be provided a full copy of the protocol along with pertinent documents 
prior to the first meeting.  Documents may be provided via s ecure email or in hard copy.  
Hard copies of any documents are considered confidential, and will be mailed via intra -office 
mail or certified carrier. Updated or new documents will be distributed by the DSMB 
coordinator.  
 
Scheduled Reports:  
The study team s hould provide reports at least a week prior to the date of the meeting. The 
study team must submit subject summary reports to the DSMB Chair and Medical Safety 
Monitor within 30 days of each completed baseline visit, and thereafter, prior to each DSMB 
meet ing, or as requested by the DSMB..  
 
DSMB Report Format:  
DSMB reports will include the following:  
1. Accrual/Recruitment Information – include number of patients screened, enrolled, 
completed, withdrawn and reasons for withdrawals if any. For multi -site studie s include 
distribution by  site. 
2. Characteristics  of Subjects  Enrolled  – include  gender,  ethnicity  (Hispanic/  Non-Hispanic), 
race: White, Black/African American,  etc. 
3. Study  information  – table  with age, gender,  missed  doses,  extra  doses  if any, PTT, 
whether  hypertensive  or not, NIH stoke  scale  before  and after intervention.  
4. Adverse events – include description, grade, expectedness,  relatedness.  
5. Compliance with protocol – include protocol  deviations.  
6. Any other information as requested by the DSMB or Study  P.I. 
 
Safety Reports:  
1. Serious Adverse Events (SAE) that are determined by the PI to be unexpected + related 
will be submitted to the DSMB within 7 calendar days of the determination by telephone  or 
fax; Submit written report no later than 15 calendar days of the determination.  
2. All other SAEs will be collected and submitted with the standard DSMB reports as 
described  above.  
 
Meetings:  
The first meeting will be held at trial initiation and after the 5th subject has completed the 
baseline infusion visit. Subseque nt meetings will be held after every 6 months, or as needed, 
at the discretion of the Chair to address safety concerns.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 48 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   Meetings may be in person or via teleconference, depending upon the schedule of the 
members. If members of the DSMB cannot  attend a scheduled meeting, the members 
present may decide the meeting will be cancelled and rescheduled to reconvene at the 
earliest possible time.  
 
The Principal Investigator and research team will be notified of planned meetings no less 
than three week s prior to the meeting date. The Principal Investigator will be expected to 
submit the required reports at least two weeks before to the scheduled meeting.  
 
The Principal Investigator and/or study team members will attend regularly scheduled open 
DSMB meet ings to provide specific clarification or respond to issues. The DSMB may invite 
guests to meetings for their expertise or for needed information. Discussion will focus on the 
conduct and progress of the study with special attention to the aggregate safety  and efficacy 
data. The Principal Investigator may present summary statements of previously submitted 
updates, adverse events, etc. Review and discussion of unblinded primary outcome data will 
be limited to voting DSMB members during closed session meeting s, or at the discretion of 
the DSMB Chair.  
 
Recommendations:  
Following a DSMB review, the board must submit a written report to the PI. The options 
available for the outcome of the review are:  
1. Recommend continuation with no  modification,  
2. Recommend continua tion with modification(s) to  protocol,  
3. Recommend suspension of enrollment pending additional  information,  
4. Recommend  suspension  of all trial activities  pending  additional  information,  
5. Recommend termination of  trial. 
 
Recommendations to the Principal Investigator must have majority approval by the Board 
members. Prior to dissemination, the Chair will review summary statements and 
recommendations from DSMB members.  
 
Distribution of DSMB Report:  
The DSMB Chair will formalize the recommendations in secure  email or formal letter and 
forward to the DSMB Coordinator for forwarding to the PI. The DSMB coordinator should 
forward the DSMB’s final recommendations to the Principal Investigator within 2 weeks of the 
meeting. The Principal Investigator is responsibl e for dissemination to the study team, IRB, 
FDA, and any other entity.  
 
Confidentiality:  
All materials, discussions and proceedings of the DSMB are completely confidential. 
Members and other participants in DSMB meetings are expected to maintain confidenti ality. 
 
DSMB Member Acknowledgement:  
DSMB members will confirm their understanding of the DSMB Charter, roles, responsibilities 
and disclosure of conflict of interests by e -mail acknowledgement.  
ACT for CP Protocol V18  
Document Version Date: 18 OCT 2017  Page 49 of 49  IRB NUMBER: HSC -MS-12-0876 
IRB APPROVAL DATE: 10/23/2017   17. Appendix D: Maternal Infectious Disease Tes ting 
  
FDA 21 CFR part 1271 requires donor eligibility determination, based on donor screening 
and testing for relevant communicable diseases and disease agents, for all human cells, 
tissues and cellular & tissue -based products (HCT/P) collected on or afte r May, 2005.  
However, 21 CFR part 1271.90 allows exceptions to this requisite and also elaborates on the 
labeling requirements for these special cases. The relevant exception to this protocol states 
that “You are not required to make a donor eligibility de termination under 1271.50 or to 
perform donor screening or testing under 1271.75, 1271.80 and 1271.85 for: (1) Cells and 
tissues for autologous use”.  
Nevertheless, we have chosen to perform maternal infectious disease markers (IDM) testing 
in this protocol. The maternal IDM results (if available) will be released to the research team 
along with the cord blood sterility and cell count information after informed consent and 
permission for releasing the test results have been obtained from the parent(s ). The IDM 
tests include: Human Immunodeficiency Virus (HIV) type 1, HIV type 2, Hepatitis B virus, 
Hepatitis C virus, Human T -cell lymphotrophic virus (HTLV) type 1, HTLV type 2, and 
Syphilis.  
Again, donor eligibility will not be determined for autologous  infusions but specific labeling 
rules will be applied. The subject will be excluded from the study if any IDM result is positive 
or reactive EXCEPT for the following cases:  
 Donor is CMV positive. Since CMV infection is not a relevant communicable disease or 
disease  agent,  the product  will not be excluded  but will require  specific  labeling.  
 If donor mother screens HBcAb reactive and HBsAg non -reactive, the product will not  be 
excluded but will require specific  labeling.  
 For syphilis, if donor tests reactive  on a NON -treponemal screening and non -reactive on  a 
specific treponemal confirmatory test, the product will not be excluded but will require 
specific  labeling.  
Per CBR, less than 10% of cord blood collections do not have maternal IDM testing 
performed. In  the event that a subject meets criteria for study entry, but CBR does not have 
the maternal IDM results, the parent(s) will be able to submit IDM results that were performed 
during the hospital admission for delivery. If the IDM tests were not completed d uring the 
pregnancy, the mother will be required to have IDM testing completed at her expense and the 
correspondent lab results submitted to the PI.  
Whenever applicable, HCT/P must be prominently labeled per 21 CFR 1271.90 as follows:  
Label Type  Usage  
“FOR AUTOLOGOUS USE ONLY”  On all autologous products  
 
“Warning: Advise Patient of Communicable Disease 
Risk”  If the result of any screening or testing performed 
indicate the presence of relevant communicable 
disease agent. For example, medical and/or 
family history puts donor at high risk for acquiring 
communicable disease agent.  
“Warning: Reactive test results for 
(name of disease agent or disease)”  If the result of any screening or testing performed 
is positive or reactive  
“Advise recipient that screening and testing of the donor 
is not performed at the time of cryopreservation of the 
cells or tissues but have been performed subsequently”  Screening or testing not performed at the time of 
cryopreservation but at later time  
 Refer to the Chemistry  and Manufacturing Section of the IND for more detailed information.  